<!DOCTYPE html>



<html lang="en">



	<meta charset="UTF-8">

	<meta name="viewport" content="width=device-width, initial-scale=1.0">

	<style>


    .node {

        stroke: #fff;

        stroke-width: 2px;

    }

    

    .link {

        stroke: #777;

        stroke-width: 2px;

    }



</style>

<body>

<a href="https://riskrunners.com">Home</a><br>




<a href="#risk_factors">Jump to Risk Factors</a><br>



<a href="#industry">Jump to Industries</a><br>


<a href="#exposure">Jump to Exposures</a><br>


<a href="#event_code">Jump to Event Codes</a><br>


<a href="#wiki">Jump to Wiki Summary</a><br><br>


    <script src="https://d3js.org/d3.v3.min.js"></script>

    <script>


// set a width and height for our SVG

var width = 3000,


    height = 3000;

    
// setup links

var links =     [
{source: "START_HERE", target: "3: commercialize", fill: "#fae7b5"},
{source: "3: commercialize", target: "3: candidates", fill: "#fae7b5"},
{source: "3: candidates", target: "3: United States ", fill: "#fae7b5"},
{source: "3: United States ", target: "3: additional research", fill: "#fae7b5"},
{source: "3: additional research", target: "3: development", fill: "#fae7b5"},
{source: "3: development", target: "3: successfully", fill: "#fae7b5"},
{source: "3: successfully", target: "3: expensive preclinical", fill: "#fae7b5"},
{source: "3: expensive preclinical", target: "3: clinical testing", fill: "#fae7b5"},
{source: "3: clinical testing", target: "3: confirmatory pivotal", fill: "#fae7b5"},
{source: "3: confirmatory pivotal", target: "3: Phase III ", fill: "#fae7b5"},
{source: "3: Phase III ", target: "3: lead product candidate", fill: "#fae7b5"},
{source: "3: lead product candidate", target: "3: successfully improve andor automate", fill: "#fae7b5"},
{source: "3: successfully improve andor automate", target: "3: manufacturing process", fill: "#fae7b5"},
{source: "3: manufacturing process", target: "3: US Food and Drug Administration or FDA ", fill: "#fae7b5"},
{source: "3: commercialize", target: "5: Favorable ", fill: "#1a1110"},
{source: "5: Favorable ", target: "5: earlier stage", fill: "#1a1110"},
{source: "5: earlier stage", target: "5: clinical trials", fill: "#1a1110"},
{source: "5: clinical trials", target: "5: later stage", fill: "#1a1110"},
{source: "5: later stage", target: "5: trials will also", fill: "#1a1110"},
{source: "5: trials will also", target: "5: demonstrate", fill: "#1a1110"},
{source: "5: demonstrate", target: "5: product candidate", fill: "#1a1110"},
{source: "5: Favorable ", target: "6: development efforts may fail", fill: "#9bddff"},
{source: "6: development efforts may fail", target: "6: preclinical studies", fill: "#9bddff"},
{source: "6: preclinical studies", target: "6: clinical trial data", fill: "#9bddff"},
{source: "6: clinical trial data", target: "6: product candidates", fill: "#9bddff"},
{source: "6: product candidates", target: "6: successfully", fill: "#9bddff"},
{source: "6: successfully", target: "6: improved andor automated", fill: "#9bddff"},
{source: "6: improved andor automated", target: "6: manufacturing systems", fill: "#9bddff"},
{source: "6: development efforts may fail", target: "7: product development efforts", fill: "#808080"},
{source: "7: product development efforts", target: "7: cannot assure", fill: "#808080"},
{source: "7: cannot assure", target: "7: commercialize", fill: "#808080"},
{source: "7: commercialize", target: "7: product candidates currently under development", fill: "#808080"},
{source: "7: product development efforts", target: "10: focused on product development", fill: "#967117"},
{source: "10: focused on product development", target: "10: generated significant", fill: "#967117"},
{source: "10: generated significant", target: "10: revenue from commercial sales", fill: "#967117"},
{source: "10: focused on product development", target: "16: must demonstrate", fill: "#f400a1"},
{source: "16: must demonstrate", target: "16: product candidates satisfy rigorous", fill: "#f400a1"},
{source: "16: product candidates satisfy rigorous", target: "16: regulatory", fill: "#f400a1"},
{source: "16: regulatory", target: "16: authorities", fill: "#f400a1"},
{source: "16: authorities", target: "16: United States ", fill: "#f400a1"},
{source: "16: must demonstrate", target: "32: marketing approval from", fill: "#900"},
{source: "32: marketing approval from", target: "32: postmarketing requirements such as", fill: "#900"},
{source: "32: postmarketing requirements such as", target: "32: advertising requirements restrictions", fill: "#900"},
{source: "32: advertising requirements restrictions", target: "32: limitations", fill: "#900"},
{source: "32: limitations", target: "32: warnings precautions contraindications", fill: "#900"},
{source: "32: warnings precautions contraindications", target: "32: impact on", fill: "#900"},
{source: "32: impact on", target: "32: future profitability", fill: "#900"},
{source: "32: future profitability", target: "32: future products", fill: "#900"},
{source: "32: future products", target: "32: continued compliance with regulatory requirements", fill: "#900"},
{source: "32: continued compliance with regulatory requirements", target: "32: submitting products", fill: "#900"},
{source: "32: submitting products", target: "32: compliance prohibiting", fill: "#900"},
{source: "32: compliance prohibiting", target: "32: suspending manufacturing", fill: "#900"},
{source: "32: suspending manufacturing", target: "32: withdrawing marketing clearance", fill: "#900"},
{source: "32: marketing approval from", target: "53: European Directive ", fill: "#872657"},
{source: "53: European Directive ", target: "53: expend significant additional funds", fill: "#872657"},
{source: "53: expend significant additional funds", target: "53: operations", fill: "#872657"},
{source: "53: European Directive ", target: "START_HERE", fill: "#872657"}]; 
    // create empty nodes array
    var nodes = {};
	var colorFill = [];
	
    // compute nodes from links data
    links.forEach(function(link) {
        link.source = nodes[link.source] ||
            (nodes[link.source] = {name: link.source});
        link.target = nodes[link.target] ||
            (nodes[link.target] = {name: link.target});
		colorFill.push({name: link.source.name, fill: link.fill });
		colorFill.push({name: link.target.name, fill: link.fill });
    });
	
	console.log(colorFill);


    // add a SVG to the body for our viz
    var svg=d3.select('body').append('svg')
        .attr("viewBox", "0 0 " + width + " " + height );

    // use the force
    var force = d3.layout.force()
		.charge(-5000)
		.gravity(0.3)
        .size([width, height])
        .nodes(d3.values(nodes))
        .links(links)
        .on("tick", tick)
        .linkDistance(200)
        .start();

    // add links
    var link = svg.selectAll('.link')
        .data(links)
        .enter().append('line')
        .attr('class', 'link'); 

    // add nodes
    var node = svg.selectAll('.node')
        .data(force.nodes())
        .enter().append('circle')
        .attr('class', 'node')
        .attr('r', width * 0.0035)
		.style("fill", function(d) {
									for (var i = 0; i < colorFill.length; i++) {
										//console.log(d.name);
										if(colorFill[i].name == d.name){
											console.log(colorFill[i].fill);
											return colorFill[i].fill;
										}
									} return "#555";
									
									});
	var label = svg.selectAll(null)
		.data(force.nodes())
		.enter()
		.append("text")
		.text(function (d) { return d.name; })
		.style("text-anchor", "middle")
		.style("fill", "#555")
		.style("font-family", "Arial")
		.style("font-size", 34);


    // what to do 
    function tick(e) {
        
        node.attr('cx', function(d) { return d.x = Math.max(6, Math.min(width - 6, d.x)); })
            .attr('cy', function(d) { return d.y = Math.max(6, Math.min(height - 6, d.y)); })
            .call(force.drag);
            
        link.attr('x1', function(d) { return d.source.x; })
            .attr('y1', function(d) { return d.source.y; })
            .attr('x2', function(d) { return d.target.x; })
            .attr('y2', function(d) { return d.target.y; });
		
		label.attr("x", function(d){ return d.x; })
             .attr("y", function (d) {return d.y - 10; });
        
    }
    
</script><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='industry'>Industries</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Application Software</td>
    </tr>
    <tr>
      <td>Technology Hardware Storage and Peripherals</td>
    </tr>
    <tr>
      <td>Information Technology</td>
    </tr>
    <tr>
      <td>Technology Hardware and Equipment</td>
    </tr>
    <tr>
      <td>Health Care Facilities</td>
    </tr>
    <tr>
      <td>Advertising</td>
    </tr>
    <tr>
      <td>Asset Management and Custody Banks</td>
    </tr>
    <tr>
      <td>Health Care Distribution and Services</td>
    </tr>
    <tr>
      <td>Trading Companies and Distributors</td>
    </tr>
    <tr>
      <td>Pharmaceuticals Biotechnology and Life Sciences</td>
    </tr>
    <tr>
      <td>Biotechnology</td>
    </tr>
    <tr>
      <td>Telecommunication Services</td>
    </tr>
    <tr>
      <td>Investment Banking and Brokerage</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='exposure'>Exposures</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Express intent</td>
    </tr>
    <tr>
      <td>Intelligence</td>
    </tr>
    <tr>
      <td>Provide</td>
    </tr>
    <tr>
      <td>Military</td>
    </tr>
    <tr>
      <td>Regime</td>
    </tr>
    <tr>
      <td>Political reform</td>
    </tr>
    <tr>
      <td>Rights</td>
    </tr>
    <tr>
      <td>Ease</td>
    </tr>
    <tr>
      <td>Judicial</td>
    </tr>
    <tr>
      <td>Leadership</td>
    </tr>
    <tr>
      <td>Cooperate</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='event_code'>Event Codes</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Agree</td>
    </tr>
    <tr>
      <td>Complain</td>
    </tr>
    <tr>
      <td>Yield to order</td>
    </tr>
    <tr>
      <td>Force</td>
    </tr>
    <tr>
      <td>Demand</td>
    </tr>
    <tr>
      <td>Accident</td>
    </tr>
    <tr>
      <td>Warn</td>
    </tr>
    <tr>
      <td>Request</td>
    </tr>
    <tr>
      <td>Reward</td>
    </tr>
    <tr>
      <td>Solicit support</td>
    </tr>
    <tr>
      <td>Yield</td>
    </tr>
    <tr>
      <td>Promise policy support</td>
    </tr>
    <tr>
      <td>Adjust</td>
    </tr>
    <tr>
      <td>Vote</td>
    </tr>
    <tr>
      <td>Sports contest</td>
    </tr>
    <tr>
      <td>Acknowledge responsibility</td>
    </tr>
    <tr>
      <td>Yield position</td>
    </tr>
    <tr>
      <td>Riot</td>
    </tr>
    <tr>
      <td>Expel</td>
    </tr>
    <tr>
      <td>Sanction</td>
    </tr>
    <tr>
      <td>Human death</td>
    </tr>
    <tr>
      <td>Host meeting</td>
    </tr>
    <tr>
      <td>Psychological state</td>
    </tr>
    <tr>
      <td>Military blockade</td>
    </tr>
    <tr>
      <td>Grant</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='wiki'>Wiki</th>
      <th>Wiki Summary</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Candidate">Candidate</a></td>
      <td>A candidate, or nominee, is the prospective recipient of an award or honor, or a person seeking or being considered for some kind of position; for example:\n\nto be elected to an office — in this case a candidate selection procedure occurs.\nto receive membership in a  group"Nomination" is part of the process of selecting a candidate for either election to an office by a political party, or the bestowing of an honor or award.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Candidates_of_the_2022_Australian_federal_election">Candidates of the 2022 Australian federal election</a></td>
      <td>This is a list of confirmed candidates in ballot paper order for the 2022 Australian federal election.At the close of nominations a total of 1,624 candidates had stood for election, of which 1,203 were House of Representatives candidates and 421 were Senate candidates.\n\n\n== Retiring members ==\nThe seat of Spence (SA) was vacant following the resignation of Nick Champion (Labor) on 22 February 2022 to contest the South Australian state election.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Write-in_candidate">Write-in candidate</a></td>
      <td>A write-in candidate is a candidate whose name does not appear on the ballot but seeks election by asking voters to cast a vote for the candidate by physically writing in the person's name on the ballot. Depending on electoral law it may be possible to win an election by winning a sufficient number of such write-in votes, which count equally as if the person was formally listed on the ballot.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Candidates_Tournament">Candidates Tournament</a></td>
      <td>The Candidates Tournament (or in some periods Candidates Matches) is a chess tournament organized by FIDE, chess's international governing body, since 1950, as the final contest to determine the challenger for the World Chess Championship. The winner of the Candidates earns the right to a match for the World Championship against the incumbent World Champion.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Perennial_candidate">Perennial candidate</a></td>
      <td>A perennial candidate is a political candidate who frequently runs for elected office and rarely, if ever, wins. Perennial candidates' existence lies in the fact that in some countries, there are no laws that limit a number of times a person can run for office, or laws that impose a non-negligible financial penalty on registering to run for election.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Candidates_Tournament_2022">Candidates Tournament 2022</a></td>
      <td>The 2022 Candidates Tournament is an upcoming eight-player chess tournament, to decide the challenger for the World Chess Championship 2023. The tournament is scheduled to take place at the Palace of Santoña in Madrid, Spain from June 16 to July 5, 2022, with the World Championship to follow in early 2023.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/2022_Lebanese_general_election">2022 Lebanese general election</a></td>
      <td>General elections were held in Lebanon on 15 May 2022. The country has for several years been the subject of chronic political instability as well as a serious economic crisis aggravated by the 2020 explosions that hit the Port of Beirut and faced large-scale demonstrations against the political class.Hezbollah and their allies lost their parliamentary majority but still won the Parliament speaker election.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Officer_candidate">Officer candidate</a></td>
      <td>Officer candidate or officer aspirant (OA) is a rank in some militaries of the world that is an appointed position while a person is in training to become an officer.  More often than not, an officer candidate was a civilian who applied to join the military directly as an officer.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Research_and_development">Research and development</a></td>
      <td>Research and development (R&amp;D or R+D), known in Europe as research and technological development (RTD), is the set of innovative activities undertaken by corporations or governments in developing new services or products, and improving existing ones. Research and development constitutes the first stage of development of a potential new service or the production process.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Aerie_Pharmaceuticals">Aerie Pharmaceuticals</a></td>
      <td>Aerie Pharmaceuticals Inc. (Nasdaq: AERI) is a publicly traded, clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with glaucoma and other diseases of the eye.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Manufacturing">Manufacturing</a></td>
      <td>Manufacturing is the creation or production of goods with the help of equipment, labor, machines, tools, and chemical or biological processing or formulation. It is the essence of secondary sector of the economy.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Halozyme">Halozyme</a></td>
      <td>Halozyme Therapeutics is an American biotechnology company that develops novel oncology therapies designed to target the tumor microenvironment and licenses a novel drug delivery technology through corporate partnerships.\nThe company was founded in 1998 and went public in 2004.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Medicago_Inc.">Medicago Inc.</a></td>
      <td>Medicago Inc. is a privately-owned Canadian biotechnology company focused on the discovery, development, and commercialization of virus-like particles using plants as "bioreactors" to produce proteins as candidate vaccines and medications.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/MediGene">MediGene</a></td>
      <td>Medigene AG (FSE: MDG1, ISIN DE000A1X3W00, Prime Standard) is a publicly listed biotechnology company headquartered in Martinsried near Munich, Germany. Medigene is working on the development of immunotherapies to enhance T cell activity against solid cancers.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Bavarian_Nordic">Bavarian Nordic</a></td>
      <td>Bavarian Nordic A/S is a fully integrated biotechnology company focused on the development, manufacturing and commercialization of vaccines for infectious diseases and cancer immunotherapies. The company is headquartered in Hellerup, Denmark, with a manufacturing facility in Kvistgård, and an additional site in Hørsholm.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Takeda_Oncology">Takeda Oncology</a></td>
      <td>Takeda Oncology (originally Millennium Pharmaceuticals) is a biopharmaceutical company based in Cambridge, Massachusetts. It is a fully owned subsidiary of Takeda Pharmaceutical.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Minimum_viable_product">Minimum viable product</a></td>
      <td>A minimum viable product (MVP) is a version of a product with just enough features to be usable by early customers who can then provide feedback for future product development.A focus on releasing an MVP means that developers potentially avoid lengthy and (ultimately) unnecessary work. Instead, they iterate on working versions and respond to feedback, challenging and validating assumptions about a product's requirements.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Product_lifecycle">Product lifecycle</a></td>
      <td>In industry, Product Lifecycle Management (PLM) is the process of managing the entire lifecycle of a product from its inception through the engineering, design and manufacture, as well as the service and disposal of manufactured products. PLM integrates people, data, processes and business systems and provides a product information backbone for companies and their extended enterprises.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Regulation">Regulation</a></td>
      <td>Regulation is the management of complex systems according to a set of rules and trends. In systems theory, these types of rules exist in various fields of biology and society, but the term has slightly different meanings according to context.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Tesla,_Inc.">Tesla, Inc.</a></td>
      <td>Tesla, Inc. ( TESS-lə or  TEZ-lə) is an American automotive and clean energy company based in Austin, Texas.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Osborne_effect">Osborne effect</a></td>
      <td>The Osborne effect is a social phenomenon of customers canceling or deferring orders for the current, soon-to-be-obsolete product as an unexpected drawback of a company's announcing a future product prematurely. It is an example of cannibalization.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Apple_community">Apple community</a></td>
      <td>The Apple community is a group of people interested in Apple Inc. and its products, who report information in various media.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Product-family_engineering">Product-family engineering</a></td>
      <td>Product-family engineering (PFE), also known as product-line engineering, is based on the ideas of "domain engineering" created by the Software Engineering Institute, a term coined by James Neighbors in his 1980 dissertation at University of California, Irvine. Software product lines are quite common in our daily lives, but before a product family can be successfully established, an extensive process has to be followed.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Unreal_Engine">Unreal Engine</a></td>
      <td>Unreal Engine (UE) is a 3D computer graphics game engine developed by Epic Games, first showcased in the 1998 first-person shooter game Unreal. Initially developed for PC first-person shooters, it has since been used in a variety of genres of games and has seen adoption by other industries, most notably the film and television industry.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Media_Factory">Media Factory</a></td>
      <td>Media Factory (メディアファクトリー, Mediafakutorī), formerly Media Factory, Inc. (株式会社メディアファクトリー, Kabushiki gaisha Mediafakutorī) is a Japanese publisher and brand company of Kadokawa Future Publishing.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Operation_Mincemeat">Operation Mincemeat</a></td>
      <td>Operation Mincemeat was a successful British deception operation of the Second World War to disguise the 1943 Allied invasion of Sicily. Two members of British intelligence obtained the body of Glyndwr Michael, a tramp who died from eating rat poison, dressed him as an officer of the Royal Marines and placed personal items on him identifying him as the fictitious Captain (Acting Major) William Martin.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Bitwise_operation">Bitwise operation</a></td>
      <td>In computer programming, a bitwise operation operates on a bit string, a bit array or a binary numeral (considered as a bit string) at the level of its individual bits. It is a fast and simple action, basic to the higher-level arithmetic operations and directly supported by the processor.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Special_Activities_Center">Special Activities Center</a></td>
      <td>The Special Activities Center (SAC) is a division of the Central Intelligence Agency responsible for covert operations and paramilitary operations. The unit was named Special Activities Division (SAD) prior to 2015.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Operations_management">Operations management</a></td>
      <td>Operations management is an area of management concerned with designing and controlling the process of production and redesigning business operations in the production of goods or services. It involves the responsibility of ensuring that business operations are efficient in terms of using as few resources as needed and effective in meeting customer requirements.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Operations_research">Operations research</a></td>
      <td>Operations research (British English: operational research), often shortened to the initialism OR, is a discipline that deals with the development and application of advanced analytical methods to improve decision-making. It is sometimes considered to be a subfield of mathematical sciences.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Emergency_operations_center">Emergency operations center</a></td>
      <td>An emergency operations center (EOC) is a central command and control facility responsible for carrying out the principles of emergency preparedness and emergency management, or disaster management functions at a strategic level during an emergency, and ensuring the continuity of operation of a company, political subdivision or other organization.\nAn EOC is responsible for strategic direction and operational decisions and does not normally directly control field assets, instead leaving tactical decisions to lower commands.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Surgery">Surgery</a></td>
      <td>Surgery is a medical or dental specialty that uses operative manual and instrumental techniques on a person to investigate or treat a pathological condition such as a disease or injury, to help improve bodily function, appearance, or to repair unwanted ruptured areas.\nThe act of performing surgery may be called a surgical procedure, operation, or simply "surgery".</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Special_operations">Special operations</a></td>
      <td>Special operations (S.O.) are military activities conducted, according to NATO, by "specially designated, organized, selected, trained, and equipped forces using unconventional techniques and modes of employment". Special operations may include reconnaissance, unconventional warfare, and counter-terrorism actions, and are typically conducted by small groups of highly-trained personnel, emphasizing sufficiency, stealth, speed, and tactical coordination, commonly known as "special forces".</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='risk_factors'>Risk Factors</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>ISOLAGEN INC      Item 1A                Risk Factors       Potential <font color="blue">investors should carefully</font> consider the <font color="blue">following risk factors</font>     prior to making any <font color="blue"><font color="blue">investment</font> decisions</font> regarding our securities</td>
    </tr>
    <tr>
      <td>We may be unable to <font color="blue"><font color="blue">successfully</font> <font color="blue">commercialize</font></font> our Isolagen Process or any     of our <font color="blue">product <font color="blue">candidates</font> currently under <font color="blue">development</font></font></td>
    </tr>
    <tr>
      <td>Before we can <font color="blue">commercialize</font> our Isolagen Process or any of our product     <font color="blue">candidates</font> in the <font color="blue">United States</font>, we will need to:       ·       conduct substantial <font color="blue"><font color="blue">additional</font> research</font> and <font color="blue">development</font>;       ·        <font color="blue">successfully</font>  complete lengthy and expensive pre-clinical and     <font color="blue">clinical testing</font>, including the <font color="blue">confirmatory pivotal</font> <font color="blue">Phase III </font>clinical     trial for our <font color="blue">lead <font color="blue">product candidate</font></font>;       ·       <font color="blue">successfully</font> improve and/or automate our <font color="blue"><font color="blue">manufacturing</font> process</font>; and       ·       obtain US Food and Drug Administration, or FDA, approvals</td>
    </tr>
    <tr>
      <td><font color="blue">Commercialization </font>of our Isolagen Process involves a high degree of risk and     may take <font color="blue">several years</font></td>
    </tr>
    <tr>
      <td><font color="blue">Favorable </font>results in pre-clinical or <font color="blue">earlier stage</font>     <font color="blue"><font color="blue">clinical trial</font>s</font> do not ensure that the results of <font color="blue">later stage</font> and pivotal     <font color="blue">trials will also</font> be favorable or adequate to <font color="blue">demonstrate</font> the safety or     efficacy of the <font color="blue">product candidate</font> or to obtain FDA approval</td>
    </tr>
    <tr>
      <td>Our product     <font color="blue">development</font> efforts may fail for many reasons, including:       ·       failures in pre-clinical studies;       ·       insufficient <font color="blue"><font color="blue">clinical trial</font> data</font> to support the safety or efficacy     of our product <font color="blue">candidates</font>;       ·        failure  to  <font color="blue">successfully</font> implement improved and/or automated     <font color="blue"><font color="blue">manufacturing</font> systems</font>; or       ·       failure to obtain the required FDA approvals</td>
    </tr>
    <tr>
      <td>Even if our product <font color="blue">development</font> efforts are successful, we <font color="blue">cannot assure</font> you     that we will be able to <font color="blue">commercialize</font> our Isolagen Process or any of our     <font color="blue">product <font color="blue">candidates</font> currently under <font color="blue">development</font></font></td>
    </tr>
    <tr>
      <td>In that event, we will be     unable to <font color="blue">generate <font color="blue"><font color="blue">significant</font> revenue</font></font>, and our business will fail</td>
    </tr>
    <tr>
      <td>20     ______________________________________________________________________       We have not <font color="blue">generated <font color="blue"><font color="blue">significant</font> revenue</font> from commercial sales</font> of our     products  to  date,  and  we do not know whether we <font color="blue">will ever generate</font>     <font color="blue"><font color="blue">significant</font> revenue</font></td>
    </tr>
    <tr>
      <td>We are <font color="blue">focused on</font> product <font color="blue">development</font> and have not <font color="blue">generated <font color="blue">significant</font></font>     <font color="blue">revenue from commercial sales</font> of our products to date</td>
    </tr>
    <tr>
      <td>We have incurred     operating  <font color="blue">losses since</font> our inception</td>
    </tr>
    <tr>
      <td>Our revenue for the years ended     <font color="blue">December </font>31,  2005  2004 and 2003 was dlra8dtta75 million, dlra4dtta18 million and     dlra0dtta45 million, <font color="blue">respectively</font></td>
    </tr>
    <tr>
      <td>Our net loss for the years ended <font color="blue">December </font>31,     2005, 2004 and 2003 was dlra35dtta8 million, dlra21dtta5 million and dlra11dtta3 million,     <font color="blue">respectively</font></td>
    </tr>
    <tr>
      <td>As of <font color="blue">December </font>31, 2005, we had an accumulated <font color="blue">development</font>     <font color="blue">stage net loss attributable</font> to <font color="blue">common <font color="blue">shareholder</font>s</font> of dlra91dtta3 million</td>
    </tr>
    <tr>
      <td>We currently have no product <font color="blue">candidates</font> for sale in the <font color="blue">United States</font>, and     we cannot guarantee that we will ever have marketable products in the United     States</td>
    </tr>
    <tr>
      <td>We must <font color="blue">demonstrate</font> that our product <font color="blue">candidates</font> satisfy rigorous     standards  of  safety and efficacy before the FDA and other <font color="blue">regulatory</font>     <font color="blue">authorities</font> in the <font color="blue"><font color="blue">United States</font> </font>and abroad <font color="blue">will approve</font> the products for     commercial  marketing</td>
    </tr>
    <tr>
      <td>We will need to <font color="blue">conduct <font color="blue">significant</font> <font color="blue">additional</font></font>     research,  pre<font color="blue">clinical testing</font> and <font color="blue">clinical testing</font> before we can file     <font color="blue"><font color="blue">application</font>s with</font> the FDA for approval of our product <font color="blue">candidates</font></td>
    </tr>
    <tr>
      <td>We must     also  develop, validate and obtain FDA approval of any improved and/or     automated <font color="blue"><font color="blue">manufacturing</font> process</font></td>
    </tr>
    <tr>
      <td>In addition, to <font color="blue">compete <font color="blue"><font color="blue">effective</font>ly</font></font> our     future  <font color="blue">products must</font> be easy to use, cost-<font color="blue">effective</font> and economical to     <font color="blue">manufacture</font>  on  a  commercial  scale</td>
    </tr>
    <tr>
      <td>We may not achieve any of these     <font color="blue">objectives</font></td>
    </tr>
    <tr>
      <td>We expect to continue to <font color="blue">incur losses as</font> we research, develop and seek     <font color="blue">regulatory</font> approvals for our product <font color="blue">candidates</font></td>
    </tr>
    <tr>
      <td>If our product <font color="blue">candidates</font>     fail in <font color="blue"><font color="blue">clinical trial</font>s</font> or do not gain <font color="blue">regulatory</font> approval, if our product     <font color="blue">candidates</font> do not achieve <font color="blue">market <font color="blue">acceptance</font></font>, or if we do not succeed in     <font color="blue"><font color="blue">effective</font>ly</font>  and  <font color="blue">efficiently</font>  <font color="blue">implementing</font>  <font color="blue"><font color="blue">manufacturing</font> process</font> and     <font color="blue"><font color="blue">technology</font> <font color="blue">improvements</font></font> to make our <font color="blue">product <font color="blue">commercially viable</font></font>, we will not     be profitable</td>
    </tr>
    <tr>
      <td>If we fail to become and <font color="blue">remain profitable</font>, or if we are     unable to fund our <font color="blue">continuing losses</font>, our business may fail</td>
    </tr>
    <tr>
      <td><font color="blue">Obtaining FDA </font>and other <font color="blue">regulatory</font> approvals is complex, time consuming and     expensive, and the outcomes are uncertain</td>
    </tr>
    <tr>
      <td>The  process  of  obtaining FDA and other <font color="blue">regulatory</font> approvals is time     consuming, expensive and <font color="blue">difficult</font> to design and implement</td>
    </tr>
    <tr>
      <td>Clinical trials     are required and the marketing and <font color="blue">manufacturing</font> of our product <font color="blue">candidates</font>     are  subject to <font color="blue">rigorous testing procedures</font></td>
    </tr>
    <tr>
      <td>We have <font color="blue">commenced initial</font>     <font color="blue">preparations</font> related to our <font color="blue">confirmatory pivotal</font> <font color="blue">Phase III </font><font color="blue">clinical trial</font>     for our <font color="blue">lead <font color="blue">product candidate</font></font></td>
    </tr>
    <tr>
      <td>Our other product <font color="blue">candidates</font> will require     <font color="blue">additional</font> <font color="blue"><font color="blue">clinical trial</font>s</font></td>
    </tr>
    <tr>
      <td>The commencement and <font color="blue">completion</font> of clinical     trials for our Isolagen Process or any of our product <font color="blue">candidates</font> could be     delayed or <font color="blue">prevented by</font> a variety of factors, including:       ·       delays in obtaining <font color="blue">regulatory</font> approvals to commence a study;       ·       delays in identifying and <font color="blue">reaching agreement on</font> acceptable terms     with prospective <font color="blue">clinical trial</font> sites;       ·       delays in the <font color="blue">enrollment</font> of subjects;       ·       lack of efficacy during <font color="blue"><font color="blue">clinical trial</font>s</font>; or       ·       <font color="blue">unforeseen safety issues</font></td>
    </tr>
    <tr>
      <td>We do not know whether our <font color="blue"><font color="blue">clinical trial</font>s</font> will need to be <font color="blue"><font color="blue">restructure</font>d</font> or     will be completed on schedule, if at all</td>
    </tr>
    <tr>
      <td><font color="blue">Significant </font>delays in clinical     <font color="blue">trials will impede</font> our ability to <font color="blue">commercialize</font> our product <font color="blue">candidates</font> and     <font color="blue">generate revenue</font>, and <font color="blue">could <font color="blue">significant</font>ly increase</font> our <font color="blue">development</font> costs</td>
    </tr>
    <tr>
      <td>21     ______________________________________________________________________       Even if <font color="blue"><font color="blue">marketing approval</font> from</font> the FDA is received, the FDA may impose     post-marketing <font color="blue"><font color="blue">requirement</font>s</font>, such as:       ·       labeling and <font color="blue">advertising</font> <font color="blue"><font color="blue">requirement</font>s</font>, <font color="blue"><font color="blue">restriction</font>s</font> or <font color="blue">limitations</font>,     including the inclusion of warnings, precautions, contra-indications or use     <font color="blue">limitations</font> that could have a material <font color="blue">impact on</font> the <font color="blue">future <font color="blue">profitability</font></font> of     our product <font color="blue">candidates</font>;       ·       testing and surveillance to monitor our <font color="blue">future products</font> and their     continued <font color="blue">compliance with</font> <font color="blue">regulatory</font> <font color="blue"><font color="blue">requirement</font>s</font>;       ·       <font color="blue">submitting products</font> for inspection and, if any inspection reveals     that the product is not in compliance, prohibiting the sale of all products;       ·       suspending <font color="blue">manufacturing</font>; or       ·       <font color="blue">withdrawing marketing clearance</font></td>
    </tr>
    <tr>
      <td>Our ability to <font color="blue"><font color="blue">effective</font>ly</font> <font color="blue">commercialize</font> our <font color="blue">dermal product</font> and our product     <font color="blue">candidates</font> depends on our ability to improve our <font color="blue"><font color="blue">manufacturing</font> process</font> and     to <font color="blue">satisfactorily validate</font> the <font color="blue">cellular expansion</font> and <font color="blue">harvesting process</font></td>
    </tr>
    <tr>
      <td>We must obtain FDA approval of our validated <font color="blue"><font color="blue">manufacturing</font> process</font> before we     can commercially <font color="blue">manufacture</font> our product <font color="blue">candidates</font> in the <font color="blue">United States</font></td>
    </tr>
    <tr>
      <td>In     addition,  we must pass a pre-approval inspection of our <font color="blue">manufacturing</font>     <font color="blue">facility</font> before we can obtain <font color="blue">marketing approval</font> for our product <font color="blue">candidates</font></td>
    </tr>
    <tr>
      <td>We intend to seek FDA approval of our <font color="blue">cellular expansion</font> <font color="blue">manufacturing</font>     <font color="blue">process as</font> a component of the BLA <font color="blue">application</font> and <font color="blue">approval process</font></td>
    </tr>
    <tr>
      <td>In order     to  obtain  approval,  all of our <font color="blue">manufacturing</font> methods, equipment and     <font color="blue">processes must <font color="blue">comply with</font></font> the FDA’s current Good Manufacturing Practices,     or cGMP, <font color="blue"><font color="blue">requirement</font>s</font></td>
    </tr>
    <tr>
      <td>We will also need to perform extensive audits of our     suppliers, vendors and <font color="blue">contract laboratories</font></td>
    </tr>
    <tr>
      <td>The cGMP <font color="blue"><font color="blue">requirement</font>s</font> govern     all areas of recordkeeping, <font color="blue">production process</font>es and controls, personnel and     <font color="blue">quality control</font></td>
    </tr>
    <tr>
      <td>To ensure that we meet these <font color="blue"><font color="blue">requirement</font>s</font>, we will expend     <font color="blue">significant</font> time, money and effort</td>
    </tr>
    <tr>
      <td>Due to the unique nature of our Isolagen     Process, we <font color="blue">cannot predict</font> the likelihood that the FDA <font color="blue">will approve</font> our     <font color="blue">facility</font> as compliant with cGMP <font color="blue"><font color="blue">requirement</font>s</font> even if we believe that we have     taken the steps <font color="blue">necessary</font> to achieve compliance</td>
    </tr>
    <tr>
      <td>Large-scale <font color="blue">improvements</font> in <font color="blue">capacity</font> and operating <font color="blue">margins depend on</font> the     <font color="blue">successful <font color="blue">implementation</font></font> of improved <font color="blue"><font color="blue">manufacturing</font> process</font>es</td>
    </tr>
    <tr>
      <td>We hope to     <font color="blue">eliminate several</font> of the steps and materials involved in our <font color="blue">current system</font>,     which we expect will lead to <font color="blue">significant</font> cost reductions in <font color="blue">both skilled</font>     labor and materials and <font color="blue">will enable scalable mass production</font> in the future</td>
    </tr>
    <tr>
      <td>However, the commercial viability of improved <font color="blue"><font color="blue">manufacturing</font> process</font>es under     <font color="blue">consideration</font>  are  uncertain,  and  we do not know whether we will be     successful in <font color="blue">implementing</font> such improved <font color="blue"><font color="blue">manufacturing</font> process</font>es, validating     the  safety  and  efficacy  of these processes, obtaining the required     <font color="blue">scalability</font>, achieving cost savings or obtaining FDA approval of these     processes</td>
    </tr>
    <tr>
      <td>Our previous and current <font color="blue"><font color="blue">clinical trial</font>s</font> are <font color="blue">conducted using</font> a     manual process, rather than a more automated <font color="blue"><font color="blue">manufacturing</font> process</font></td>
    </tr>
    <tr>
      <td>The FDA, in its <font color="blue">regulatory</font> <font color="blue">discretion</font>, may require us to undergo <font color="blue">additional</font>     <font color="blue"><font color="blue">clinical trial</font>s</font> <font color="blue">with respect</font> to any new or improved <font color="blue"><font color="blue">manufacturing</font> process</font> we     develop or utilize, in the future, if any</td>
    </tr>
    <tr>
      <td>This <font color="blue">could delay</font> or prevent     approval  of  our  product  <font color="blue">candidates</font></td>
    </tr>
    <tr>
      <td>If we fail to <font color="blue"><font color="blue">comply with</font> cGMP</font>     <font color="blue"><font color="blue">requirement</font>s</font>, pass an FDA pre-approval inspection or obtain FDA approval of     our <font color="blue"><font color="blue">manufacturing</font> process</font>, we would not receive FDA approval and would be     subject to possible <font color="blue">regulatory</font> action</td>
    </tr>
    <tr>
      <td>The failure to <font color="blue">successfully</font> implement     our <font color="blue"><font color="blue">manufacturing</font> process</font> may delay or prevent our <font color="blue">future <font color="blue">profitability</font></font></td>
    </tr>
    <tr>
      <td>22     ______________________________________________________________________       Our <font color="blue">inability</font> to <font color="blue">comply with</font> <font color="blue">regulatory</font> <font color="blue"><font color="blue">requirement</font>s</font> in the <font color="blue"><font color="blue"><font color="blue">United Kingdom</font> </font>    </font>will limit or delay our ability to <font color="blue">attain <font color="blue">profitability</font></font></td>
    </tr>
    <tr>
      <td>We began limited <font color="blue">commercialization</font> of our <font color="blue">dermal product</font> in the United     Kingdom in late 2003</td>
    </tr>
    <tr>
      <td>Our <font color="blue">facility</font> in the <font color="blue"><font color="blue">United Kingdom</font> </font>was primarily     designed  to <font color="blue">demonstrate</font> the efficacy of our Isolagen Process, and has     limited <font color="blue">capacity</font></td>
    </tr>
    <tr>
      <td>In light of the <font color="blue">European <font color="blue">Directive </font></font>2004/23/EC, we may be     required to expend <font color="blue">significant</font> <font color="blue">additional</font> funds to make our UK <font color="blue">operations</font>     compliant</td>
    </tr>
    <tr>
      <td>This includes the addition of personnel, <font color="blue">introduction</font> of systems     <font color="blue">enhancements</font>,  and  possibly  the <font color="blue">establishment</font> of <font color="blue">new <font color="blue">facilities</font></font></td>
    </tr>
    <tr>
      <td>Our     <font color="blue">inability</font> to meet the <font color="blue">regulatory</font> <font color="blue"><font color="blue">requirement</font>s</font> in the <font color="blue"><font color="blue">United Kingdom</font> </font>may     limit our ability to <font color="blue">supply product</font> and to maximize this <font color="blue">market opportunity</font></td>
    </tr>
    <tr>
      <td>In order to implement the changes in the <font color="blue">facility</font> needed to <font color="blue">comply with</font> the     new Directive, it may be <font color="blue">necessary</font> for Isolagen to decrease <font color="blue">capacity</font>, or     stop production from the <font color="blue"><font color="blue">United Kingdom</font> </font><font color="blue">facility</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">dermal product</font> and our product <font color="blue">candidates</font> are all <font color="blue">derived from</font> our     Isolagen  Process</td>
    </tr>
    <tr>
      <td>If  our  Isolagen Process is found to be unsafe or     <font color="blue">in<font color="blue">effective</font></font>, our business would be <font color="blue"><font color="blue">materially</font> harmed</font></td>
    </tr>
    <tr>
      <td>Our  dermal  product that is sold in the <font color="blue"><font color="blue">United Kingdom</font> </font>and our dermal     candidate undergoing <font color="blue">clinical testing</font> in the <font color="blue">United States</font>, and our dental     product, are all <font color="blue">derived from</font> our <font color="blue">proprietary</font> Isolagen Process</td>
    </tr>
    <tr>
      <td>In addition,     we expect to utilize our Isolagen Process in the <font color="blue">development</font> of any future     products we market</td>
    </tr>
    <tr>
      <td>If these current or <font color="blue">future products</font> are found to be     unsafe or <font color="blue">in<font color="blue">effective</font></font>, we may have to modify or <font color="blue">cease production</font> of the     products</td>
    </tr>
    <tr>
      <td>As our <font color="blue">dermal product</font> and all of our product <font color="blue">candidates</font> utilize or     <font color="blue">will utilize</font> our Isolagen Process, any defects with this <font color="blue">technology</font> would     severely harm our business <font color="blue">operations</font>, since all of our primary revenue     sources would be <font color="blue">negatively</font> affected by the defects</td>
    </tr>
    <tr>
      <td>Our  ability  to  expand  our  <font color="blue">operations</font>  to  support  the full-scale     <font color="blue">commercialization</font> of our Isolagen Process is <font color="blue"><font color="blue">dependent</font> on</font> our ability to     establish new <font color="blue">manufacturing</font> <font color="blue">facilities</font></td>
    </tr>
    <tr>
      <td>None of our <font color="blue">facilities</font> were designed or have the <font color="blue">capacity</font> to support the     full-scale  <font color="blue">commercialization</font>  of  all  of our product <font color="blue">candidates</font></td>
    </tr>
    <tr>
      <td>Our     <font color="blue">manufacturing</font> <font color="blue">facility</font> in the <font color="blue"><font color="blue">United Kingdom</font> </font>was <font color="blue">designed primarily</font> to     enable  us to <font color="blue">demonstrate</font> the efficacy of our Isolagen Process, and to     provide a platform for the future <font color="blue">development</font> of our <font color="blue"><font color="blue">manufacturing</font> process</font>es     and our information and other <font color="blue">support systems</font></td>
    </tr>
    <tr>
      <td>While we have expanded our     <font color="blue">capacity</font> at that <font color="blue">facility</font>, the limited size of that <font color="blue">facility</font> represents an     <font color="blue">inherent limitation</font> of our <font color="blue">capacity</font></td>
    </tr>
    <tr>
      <td>The UK <font color="blue">facility</font> may not be able to meet     the <font color="blue">ongoing demand</font> for our <font color="blue">dermal product</font> in the <font color="blue">United Kingdom</font>, even if our     efforts to improve the <font color="blue"><font color="blue">manufacturing</font> process</font> are <font color="blue"><font color="blue">effective</font>ly</font> and timely     implemented</td>
    </tr>
    <tr>
      <td>The  failure  to  timely establish full-scale commercial     <font color="blue">manufacturing</font> <font color="blue">facilities</font> may delay or prevent our <font color="blue">future <font color="blue">profitability</font></font></td>
    </tr>
    <tr>
      <td>We plan to operate a single <font color="blue">manufacturing</font> <font color="blue">facility</font> in the <font color="blue">United States</font></td>
    </tr>
    <tr>
      <td>As     a result, if we obtain FDA approval of our <font color="blue">lead <font color="blue">product candidate</font></font>, all of     the commercial <font color="blue">manufacturing</font> for the US <font color="blue">market will</font> take place at a single     US <font color="blue">facility</font></td>
    </tr>
    <tr>
      <td>If <font color="blue">regulatory</font>, <font color="blue">manufacturing</font> or other problems require us to     <font color="blue">discontinue production at</font> that <font color="blue">facility</font>, we will not be able to supply     product in the <font color="blue">United States</font>, <font color="blue">which would <font color="blue">adversely</font> impact</font> our business</td>
    </tr>
    <tr>
      <td>Our <font color="blue">recent issuance</font> of notes or of other <font color="blue">indebtedness</font> in the <font color="blue">future may</font>     impact our <font color="blue">financial condition</font> and results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>In  November 2004,  we  completed  a  note offering in which we issued     dlra90dtta0 million  of  <font color="blue">indebtedness</font> pursuant to an indenture</td>
    </tr>
    <tr>
      <td>We may incur     <font color="blue">additional</font> <font color="blue">indebtedness</font> in the future, and the indenture does not restrict     our <font color="blue">future incurrence</font> of <font color="blue">indebtedness</font></td>
    </tr>
    <tr>
      <td>Our level of <font color="blue">indebtedness</font> will have     several  <font color="blue">significant</font>  effects  on our future <font color="blue">operations</font>, including the     following:       ·       we will be required to use a portion of our cash for the payment of     any principal or <font color="blue">interest due on</font> our outstanding <font color="blue">indebtedness</font>, including the     <font color="blue">recently issued</font> notes;       23     ______________________________________________________________________       ·       our outstanding <font color="blue">indebtedness</font> and <font color="blue">leverage will increase</font> the impact     of negative changes in general economic and industry conditions, as well as     <font color="blue"><font color="blue">competitive</font> pressures</font>; and       ·       the level of our <font color="blue">outstanding debt may affect</font> our ability to obtain     <font color="blue">additional</font> financing for working capital, <font color="blue">capital <font color="blue"><font color="blue">expenditure</font>s</font></font> or general     <font color="blue">corporate purposes</font></td>
    </tr>
    <tr>
      <td>General economic conditions, industry cycles and financial, business and     other  factors  <font color="blue">affecting</font> our <font color="blue">operations</font>, many of which are beyond our     control, may affect our <font color="blue">future performance</font></td>
    </tr>
    <tr>
      <td>As a result, these and other     <font color="blue">factors may affect</font> our ability to make principal and <font color="blue">interest payments on</font>     our <font color="blue">indebtedness</font></td>
    </tr>
    <tr>
      <td>If we cannot generate sufficient cash flow from <font color="blue">operations</font>     in the future to service our debt, we may, among other things:       ·       seek <font color="blue">additional</font> financing in the debt or <font color="blue">equity markets</font>;       ·       refinance or <font color="blue">restructure</font> all or a portion of our <font color="blue">indebtedness</font>;       ·       <font color="blue">sell selected assets</font>;       ·       reduce or delay planned <font color="blue">capital <font color="blue"><font color="blue">expenditure</font>s</font></font>; or       ·       reduce or delay planned research and <font color="blue">development</font> <font color="blue"><font color="blue">expenditure</font>s</font></td>
    </tr>
    <tr>
      <td>These  measures  might  not  be sufficient to <font color="blue">enable us</font> to service our     <font color="blue">indebtedness</font></td>
    </tr>
    <tr>
      <td>In addition, any financing, refinancing or sale of assets     might not be available, or <font color="blue"><font color="blue">available on</font> economically</font> favorable terms</td>
    </tr>
    <tr>
      <td>We may need to raise substantial <font color="blue">additional</font> capital to fund our <font color="blue">operations</font>     in the future, and we do not have any <font color="blue">future commitments</font> for capital</td>
    </tr>
    <tr>
      <td>We  believe  our <font color="blue">cash resources will</font> be sufficient to fund our planned     <font color="blue">operations</font> for at least 18 months from <font color="blue">December </font>31, 2005</td>
    </tr>
    <tr>
      <td>We are <font color="blue">focused on</font>     research and <font color="blue">development</font>, are incurring losses from <font color="blue">operations</font>, have limited     <font color="blue">capital resources</font>, and do not have access to a line of credit or other debt     <font color="blue">facility</font></td>
    </tr>
    <tr>
      <td>We may need <font color="blue">additional</font> capital in the future to execute our     business strategy, and if we are <font color="blue">unsuccessful</font> in raising such <font color="blue">additional</font>     capital we may be unable to fully execute our business <font color="blue">strategy on</font> a timely     basis, if at all</td>
    </tr>
    <tr>
      <td>If we raise <font color="blue">additional</font> capital through the issuance of     <font color="blue">debt securities</font>, the interests of our <font color="blue"><font color="blue">stockholders</font> would</font> be subordinated to     the interests of our <font color="blue">debt holders</font> and any <font color="blue">interest payments would reduce</font> the     amount of <font color="blue">cash available</font> to operate and grow our business</td>
    </tr>
    <tr>
      <td>If we raise     <font color="blue">additional</font> capital through the sale of <font color="blue">equity securities</font>, the ownership of     our current <font color="blue"><font color="blue">stockholders</font> would</font> be diluted</td>
    </tr>
    <tr>
      <td>Additionally, we do not know     whether any financing, if obtained, will be adequate to meet our capital     needs and to support our growth</td>
    </tr>
    <tr>
      <td>If <font color="blue">adequate capital cannot</font> be obtained on     satisfactory terms, we <font color="blue">may terminate</font> or delay <font color="blue">regulatory</font> approval of one or     more of our product <font color="blue">candidates</font>, curtail or delay the <font color="blue">implementation</font> of     <font color="blue"><font color="blue">manufacturing</font> process</font> <font color="blue">improvements</font> or delay the expansion of our sales and     marketing  <font color="blue">capabilities</font></td>
    </tr>
    <tr>
      <td>If we terminate or delay <font color="blue">regulatory</font> approval,     curtail or delay <font color="blue">manufacturing</font> <font color="blue">improvements</font> or delay the expansion of our     sales and marketing <font color="blue">capabilities</font>, our business may fail</td>
    </tr>
    <tr>
      <td>We have a limited operating history, and because of the emerging nature of     the markets in which we compete, our <font color="blue">historical financial data</font> is of limited     value in estimating future operating expenses</td>
    </tr>
    <tr>
      <td>Our <font color="blue">budgeted expense levels</font>     are based in part on our <font color="blue"><font color="blue">expectations</font> concerning future revenue</font></td>
    </tr>
    <tr>
      <td>However,     the size of future revenue depends on the choices and demand of <font color="blue">individuals</font>,     which are <font color="blue">difficult</font> to forecast <font color="blue">accurately</font></td>
    </tr>
    <tr>
      <td>We may be unable to adjust our     <font color="blue">operations</font> in a <font color="blue">timely manner</font> to compensate for any <font color="blue">unexpected shortfall</font> in     revenue</td>
    </tr>
    <tr>
      <td>Accordingly, a <font color="blue">significant</font> shortfall in demand for our products     could have an immediate and material adverse effect on our business, results     of <font color="blue">operations</font> and <font color="blue">financial condition</font></td>
    </tr>
    <tr>
      <td>24     ______________________________________________________________________       Further,  our  fixed  <font color="blue">manufacturing</font> costs and business <font color="blue">development</font> and     marketing expenses will increase <font color="blue">significant</font>ly as we expand our <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>To the extent that expenses precede or are not rapidly followed by increased     revenue, our business, results of <font color="blue">operations</font> and <font color="blue">financial condition</font> may be     <font color="blue">materially</font> <font color="blue">adversely</font> affected</td>
    </tr>
    <tr>
      <td>Clinical <font color="blue">trials may fail</font> to <font color="blue">demonstrate</font> the safety and efficacy of our     product <font color="blue">candidates</font>, which could prevent or <font color="blue">significant</font>ly delay <font color="blue">regulatory</font>     approval</td>
    </tr>
    <tr>
      <td>Prior to receiving approval to <font color="blue">commercialize</font> any of our product <font color="blue">candidates</font>,     we must <font color="blue">demonstrate</font> with substantial evidence from well-controlled clinical     trials, and to the <font color="blue">satisfaction</font> of the FDA and other <font color="blue">regulatory</font> <font color="blue">authorities</font>     in the <font color="blue"><font color="blue">United States</font> </font>and abroad, that our product <font color="blue">candidates</font> are both safe     and <font color="blue">effective</font></td>
    </tr>
    <tr>
      <td>We will need to <font color="blue">demonstrate</font> our product <font color="blue">candidates</font>’ efficacy     and  monitor  their <font color="blue">safety throughout</font> the process</td>
    </tr>
    <tr>
      <td>We are conducting a     <font color="blue">confirmatory pivotal</font> <font color="blue">Phase III </font><font color="blue">clinical trial</font> related to our <font color="blue">lead dermal</font>     <font color="blue">product candidate</font></td>
    </tr>
    <tr>
      <td>The success of prior pre-clinical or <font color="blue"><font color="blue">clinical trial</font>s</font> does     not  ensure  the success of these trials, which are being conducted in     <font color="blue">populations with <font color="blue">different</font> racial</font> and <font color="blue">ethnic demographics than</font> our previous     trials</td>
    </tr>
    <tr>
      <td>If these trials or future <font color="blue"><font color="blue">clinical trial</font>s</font> are <font color="blue">unsuccessful</font>, our     business  and  <font color="blue">reputation would</font> be harmed and our <font color="blue">stock price would</font> be     <font color="blue">adversely</font> affected</td>
    </tr>
    <tr>
      <td>All of our product <font color="blue">candidates</font> are prone to the risks of <font color="blue">failure inherent</font> in     biologic <font color="blue">development</font></td>
    </tr>
    <tr>
      <td>The results of early-stage <font color="blue"><font color="blue">clinical trial</font>s</font> of our     product <font color="blue">candidates</font> do not <font color="blue">necessarily predict</font> the results of later-stage     <font color="blue"><font color="blue">clinical trial</font>s</font></td>
    </tr>
    <tr>
      <td>Product <font color="blue">candidates</font> in later-stage <font color="blue"><font color="blue">clinical trial</font>s</font> may fail     to show desired safety and <font color="blue">efficacy traits despite</font> having progressed through     initial  clinical  testing</td>
    </tr>
    <tr>
      <td>Even if we believe the <font color="blue">data collected from</font>     <font color="blue"><font color="blue">clinical trial</font>s</font> of our product <font color="blue">candidates</font> is promising, this data may not be     sufficient to <font color="blue">support approval by</font> the FDA or any other US or foreign     <font color="blue">regulatory</font> approval</td>
    </tr>
    <tr>
      <td><font color="blue">Preclinical </font>and clinical data can be interpreted in     <font color="blue">different</font> ways</td>
    </tr>
    <tr>
      <td>Accordingly, FDA <font color="blue">officials could interpret such data</font> in     <font color="blue">different</font> ways than we do, which <font color="blue">could delay</font>, limit or prevent <font color="blue">regulatory</font>     approval</td>
    </tr>
    <tr>
      <td>The FDA, other <font color="blue">regulatory</font> <font color="blue">authorities</font>, our Institutional Review     Boards or we may suspend or terminate <font color="blue"><font color="blue">clinical trial</font>s</font> at any time</td>
    </tr>
    <tr>
      <td>Any     failure or <font color="blue">significant</font> delay in completing <font color="blue"><font color="blue">clinical trial</font>s</font> for our product     <font color="blue">candidates</font>, or in receiving <font color="blue">regulatory</font> approval for the sale of any products     resulting from our product <font color="blue">candidates</font>, may severely harm our business and     reputation</td>
    </tr>
    <tr>
      <td>Our operating results may fluctuate <font color="blue">significant</font>ly in the future, which may     cause our results to fall below the <font color="blue">expectations</font> of <font color="blue">securities analysts</font>,     <font color="blue">stockholders</font> and investors</td>
    </tr>
    <tr>
      <td>Our operating results may fluctuate <font color="blue">significant</font>ly in the future as a result     of a variety of factors, many of which are outside of our control</td>
    </tr>
    <tr>
      <td><font color="blue">These     </font>factors include:       ·       the level of demand for our Isolagen Process and <font color="blue">future products</font>     that we may develop;       ·       the timely and <font color="blue">successful <font color="blue">implementation</font></font> of improved <font color="blue">manufacturing</font>     processes;       ·       our ability to attract and retain <font color="blue">personnel with</font> the <font color="blue">necessary</font>     strategic, technical and creative skills required for <font color="blue">effective</font> <font color="blue">operations</font>;       ·       the amount and timing of <font color="blue"><font color="blue">expenditure</font>s</font> by <font color="blue">practitioners</font> and their     patients;       ·       <font color="blue">introduction</font> of new <font color="blue">technologies</font>;       ·       product <font color="blue">liability</font> <font color="blue">litigation</font>, class action and <font color="blue">derivative</font> action     <font color="blue">litigation</font>;       ·        the amount and timing of <font color="blue">capital <font color="blue"><font color="blue">expenditure</font>s</font></font> and other costs     relating to the expansion of our <font color="blue">operations</font>;       ·       <font color="blue"><font color="blue">government</font> regulation</font> and legal <font color="blue">development</font>s regarding our Isolagen     Process  in the <font color="blue"><font color="blue">United States</font> </font>and in the <font color="blue">foreign countries</font> in which we     operate; and       25     ______________________________________________________________________       ·       <font color="blue">general economic conditions</font></td>
    </tr>
    <tr>
      <td>As a strategic response to changes in the <font color="blue"><font color="blue">competitive</font> environment</font>, we may     from time to time make pricing, service, <font color="blue">technology</font> or <font color="blue">marketing decisions</font>     or business or <font color="blue">technology</font> <font color="blue"><font color="blue">acquisition</font>s</font> that could have a material adverse     effect on our operating results</td>
    </tr>
    <tr>
      <td>Due to any of these factors, our operating     results may fall below the <font color="blue">expectations</font> of <font color="blue">securities analysts</font>, <font color="blue">stockholders</font>     and investors in any future period, which may cause our stock price to     decline</td>
    </tr>
    <tr>
      <td>Losses <font color="blue">may continue</font> to <font color="blue">increase from current levels</font> and we <font color="blue">will continue</font> to     experience <font color="blue"><font color="blue">negative cash flow</font> as</font> we expand our <font color="blue">operations</font>, which may limit     or delay our ability to <font color="blue">become profitable</font></td>
    </tr>
    <tr>
      <td>We have expended <font color="blue">significant</font> resources on hiring of personnel, research and     <font color="blue">development</font>,  <font color="blue">advertising</font>  and expansion, and we expect these costs to     continue or rise in the future</td>
    </tr>
    <tr>
      <td>As a result, we have incurred <font color="blue">losses since</font>     our inception and expect to experience operating losses and negative cash     flow as we expand our <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>We have had limited revenue to date and     losses  from  <font color="blue">operations</font>,  therefore,  we  expect to continue to incur     <font color="blue">significant</font> <font color="blue">additional</font> costs and expenses related to:       ·       FDA <font color="blue"><font color="blue">clinical trial</font>s</font> and <font color="blue">regulatory</font> approvals;       ·       expansion of <font color="blue">laboratory</font> and <font color="blue">manufacturing</font> <font color="blue">operations</font>;       ·       research and <font color="blue">development</font>;       ·       promotional and <font color="blue">marketing activities</font>;       ·       brand <font color="blue">development</font>;       ·       <font color="blue">personnel costs</font>;       ·       <font color="blue">development</font> of <font color="blue">relationships with strategic</font> business partners,     including physicians who might use our <font color="blue">future products</font>; and       ·       <font color="blue">interest expense</font> related to the notes we <font color="blue">recently offered</font></td>
    </tr>
    <tr>
      <td>If we <font color="blue">cannot adequately manage</font> our costs and expenses, we <font color="blue">will continue</font> to     experience operating losses and <font color="blue">negative cash flow</font></td>
    </tr>
    <tr>
      <td>In particular, the costs     to improve our <font color="blue"><font color="blue">manufacturing</font> process</font> and to obtain <font color="blue">regulatory</font> approvals has     been and will be considerable and the failure to improve our <font color="blue">manufacturing</font>     process, or to obtain, or delays in obtaining, any <font color="blue">regulatory</font> approvals     could <font color="blue">materially</font> <font color="blue">adversely</font> affect our business performance and financial     results</td>
    </tr>
    <tr>
      <td>We are party to securities and <font color="blue">derivative</font> <font color="blue">litigation</font> that distracts our     <font color="blue">management</font>, is expensive to conduct and seeks a <font color="blue">damage award <font color="blue">against us</font></font></td>
    </tr>
    <tr>
      <td>We  and  certain of our current and <font color="blue">former officers</font> have been named as     <font color="blue">defendants</font> in several putative <font color="blue">shareholder</font> class action lawsuits in the     <font color="blue"><font color="blue">United States</font> </font>District Court for the Southern District of Texas and the     <font color="blue"><font color="blue">United States</font> </font>District Court for the Eastern District of Pennsylvania</td>
    </tr>
    <tr>
      <td>The     <font color="blue"><font color="blue">complaints</font> purport</font> to <font color="blue">seek unspecified damages on behalf</font> of an alleged class     of  persons  who  purchased our <font color="blue"><font color="blue">common stock</font> between</font> March 3, 2004 and     August 1, 2005</td>
    </tr>
    <tr>
      <td>The <font color="blue">complaints</font> allege that we and our officers violated     Section 10(b) and Rule 10b-5 of the <font color="blue"><font color="blue">Exchange Act</font> </font>by making <font color="blue">certain false</font>     statements and omissions to the <font color="blue">investing public</font> regarding our business     <font color="blue">operations</font>,  <font color="blue">management</font>,  and  intrinsic  value of our <font color="blue">publicly traded</font>     securities</td>
    </tr>
    <tr>
      <td>The <font color="blue">complaints</font> also allege <font color="blue">liability</font> against the individual     <font color="blue">defendants</font>  under  Section 20(a) of the <font color="blue">Exchange Act</font></td>
    </tr>
    <tr>
      <td>In addition, two     <font color="blue">stockholders</font> have filed <font color="blue">derivative</font> actions in the state court in <font color="blue">Texas     </font><font color="blue">seeking recovery on behalf</font> of Isolagen <font color="blue">against certain</font> of our current and     <font color="blue">former officers</font> and <font color="blue">directors</font>, alleging, among other things, breach of     <font color="blue">fiduciary duties</font> and other <font color="blue">wrongful conduct by</font> those individual <font color="blue">defendants</font></td>
    </tr>
    <tr>
      <td>While we have <font color="blue">directors</font> and officers <font color="blue">liability</font> insurance, it is uncertain     whether the <font color="blue">insurance will</font> be sufficient to cover all damages, if any, that     we may be required to pay</td>
    </tr>
    <tr>
      <td>In addition, the securities and       26     ______________________________________________________________________       <font color="blue">derivative</font> lawsuits may distract the attention of our <font color="blue">management</font>, and are     expensive to conduct</td>
    </tr>
    <tr>
      <td>We have and <font color="blue">may continue</font> to incur substantial legal     and other <font color="blue">professional service costs</font> in <font color="blue">connection with</font> the stockholder     lawsuits</td>
    </tr>
    <tr>
      <td>The  amount  of  any <font color="blue">future costs</font> in this <font color="blue">respect cannot</font> be     determined at this time</td>
    </tr>
    <tr>
      <td>Our  failure  to  comply  with  extensive  <font color="blue"><font color="blue">government</font>al regulation may</font>     <font color="blue">significant</font>ly affect our operating results</td>
    </tr>
    <tr>
      <td>Even if we obtain <font color="blue">regulatory</font> approval for our product <font color="blue">candidates</font>, we will     continue to be subject to extensive <font color="blue"><font color="blue">requirement</font>s</font> by a number of foreign,     national, state and <font color="blue">local agencies</font></td>
    </tr>
    <tr>
      <td>These <font color="blue"><font color="blue">regulations</font> will impact</font> many     aspects of our <font color="blue">operations</font>, including testing, research and <font color="blue">development</font>,     <font color="blue">manufacturing</font>, safety, efficacy, labeling, storage, <font color="blue">quality control</font>, adverse     event reporting, record keeping, approval, <font color="blue">advertising</font> and promotion of our     <font color="blue">future products</font></td>
    </tr>
    <tr>
      <td>The FDA enforces post-marketing <font color="blue">regulatory</font> <font color="blue"><font color="blue">requirement</font>s</font>,     including the cGMP <font color="blue"><font color="blue">requirement</font>s</font>, through periodic unannounced <font color="blue">inspections</font></td>
    </tr>
    <tr>
      <td>We do not know whether we will pass any future FDA <font color="blue">inspections</font></td>
    </tr>
    <tr>
      <td>Failure to     pass an inspection could disrupt, delay or shut down our <font color="blue">manufacturing</font>     <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>Failure to <font color="blue">comply with</font> applicable <font color="blue">regulatory</font> <font color="blue"><font color="blue">requirement</font>s</font> could,     among other things, result in:       ·       fines;       ·       changes to <font color="blue">advertising</font>;       ·       failure to obtain <font color="blue">marketing approval</font>s for our product <font color="blue">candidates</font>;       ·       revocation or suspension of <font color="blue">regulatory</font> approvals of products;       ·       product seizures or recalls;       ·        delay,  <font color="blue">interruption</font>  or suspension of product <font color="blue">manufacturing</font>,     <font color="blue">distribution</font>, marketing and sales; or       ·       civil or criminal sanctions</td>
    </tr>
    <tr>
      <td>The <font color="blue">discovery</font> of <font color="blue">previously unknown problems with</font> our <font color="blue">future products</font> may     result  in  <font color="blue"><font color="blue">restriction</font>s</font>  of  the  products, including <font color="blue">withdrawal from</font>     <font color="blue">manufacture</font></td>
    </tr>
    <tr>
      <td>In  addition,  the  FDA <font color="blue">may revisit</font> and change its prior     <font color="blue">determinations with</font> regard to the safety or efficacy of our <font color="blue">future products</font></td>
    </tr>
    <tr>
      <td>If the FDA’s position changes, we may be required to change our labeling or     cease to <font color="blue">manufacture</font> and market our <font color="blue">future products</font></td>
    </tr>
    <tr>
      <td>Even prior to any     formal  <font color="blue">regulatory</font>  action,  we  <font color="blue">could voluntarily decide</font> to cease the     <font color="blue">distribution</font> and sale or recall any of our <font color="blue">future products</font> if <font color="blue">concerns about</font>     their safety or efficacy develop</td>
    </tr>
    <tr>
      <td>In their regulation of <font color="blue">advertising</font>, the <font color="blue">FDA and the FTC </font><font color="blue">issue correspondence</font>     alleging  that  some  <font color="blue">advertising</font>  or <font color="blue">promotional practices</font> are false,     misleading or <font color="blue">deceptive</font></td>
    </tr>
    <tr>
      <td>The FDA may impose a <font color="blue">wide array</font> of <font color="blue">sanctions on</font>     companies for such <font color="blue">advertising</font> practices, which could result in any of the     following:       ·       incurring substantial expenses, including fines, penalties, legal     fees and costs to <font color="blue">comply with</font> the FDA’s <font color="blue"><font color="blue">requirement</font>s</font>;       ·       changes in the methods of marketing and <font color="blue">selling products</font>;       ·       taking FDA mandated corrective action, which may include placing     <font color="blue">advertisements</font>  or  sending  letters to <font color="blue">physicians rescinding previous</font>     <font color="blue">advertisements</font> or promotions; or       ·       <font color="blue">disruption</font> in the <font color="blue">distribution</font> of products and loss of <font color="blue">sales until</font>     <font color="blue">compliance with</font> the FDA’s position is obtained</td>
    </tr>
    <tr>
      <td>If we become subject to any of the above <font color="blue"><font color="blue">requirement</font>s</font>, it could be damaging     to our reputation and restrict our ability to sell or market our future     products, and our business <font color="blue">condition could</font> be <font color="blue">adversely</font> affected</td>
    </tr>
    <tr>
      <td>27     ______________________________________________________________________       <font color="blue">Physicians </font><font color="blue">may prescribe <font color="blue">pharmaceutical</font></font> or <font color="blue">biologic products</font> for uses that     are not described in a product’s labeling or <font color="blue">differ from</font> those <font color="blue">tested by us</font>     and <font color="blue">approved by</font> the FDA While such “off-label” uses are common and the FDA     does not regulate physicians’ choice of <font color="blue">treatments</font>, the FDA does restrict a     <font color="blue">manufacture</font>r’s communications on the subject of off-label use</td>
    </tr>
    <tr>
      <td><font color="blue">Companies     </font>cannot  promote  FDA-approved  <font color="blue">pharmaceutical</font> or <font color="blue">biologic products</font> for     off-label uses, but under certain limited <font color="blue">circumstances</font> they <font color="blue">may <font color="blue">disseminate</font></font>     to <font color="blue">practitioners</font> articles published in peer-reviewed journals</td>
    </tr>
    <tr>
      <td>To the extent     allowed by law, we intend to <font color="blue">disseminate</font> peer-reviewed articles on our     <font color="blue">future products</font> to <font color="blue">practitioners</font></td>
    </tr>
    <tr>
      <td>If, however, our <font color="blue">activities fail</font> to comply     with the FDA’s <font color="blue">regulations</font> or <font color="blue">guidelines</font>, we may be subject to warnings     from, or <font color="blue">enforcement action by</font>, the FDA       Legislative or <font color="blue">regulatory</font> reform of the <font color="blue"><font color="blue">healthcare system</font> may affect</font> our     ability to sell our <font color="blue">future products</font> profitably</td>
    </tr>
    <tr>
      <td>In both the <font color="blue"><font color="blue">United States</font> </font>and a number of foreign jurisdictions, there have     <font color="blue">been legislative</font> and <font color="blue">regulatory</font> proposals to change the <font color="blue">healthcare system</font> in     ways that <font color="blue">could impact</font> our ability to sell our <font color="blue">future products</font> profitably</td>
    </tr>
    <tr>
      <td>The FDA’s <font color="blue">policies may</font> change and <font color="blue">additional</font> <font color="blue"><font color="blue">government</font> regulation</font>s may be     enacted, which could prevent or delay <font color="blue">regulatory</font> approval of our product     <font color="blue">candidates</font></td>
    </tr>
    <tr>
      <td>We <font color="blue">cannot predict</font> the likelihood, nature or extent of adverse     <font color="blue">government</font>  regulation  that  may  arise  from  future  <font color="blue">legislation</font> or     administrative action, either in the <font color="blue"><font color="blue">United States</font> </font>or abroad</td>
    </tr>
    <tr>
      <td>If we are not     able to maintain <font color="blue">regulatory</font> compliance, we might not be permitted to market     our <font color="blue">future products</font> and our business <font color="blue">could suffer</font></td>
    </tr>
    <tr>
      <td>We conduct business in <font color="blue">foreign markets</font>, and we are subject to a variety of     <font color="blue">regulations</font> in those <font color="blue">foreign markets</font> that could have a material adverse     effect on our business in a <font color="blue">particular market</font> or in general</td>
    </tr>
    <tr>
      <td>We presently have foreign <font color="blue">operations</font> in the <font color="blue">United Kingdom</font></td>
    </tr>
    <tr>
      <td>In addition, we     intend to expand our <font color="blue">operations</font> into other <font color="blue">foreign markets</font></td>
    </tr>
    <tr>
      <td>We are already     subject to a variety of <font color="blue">regulations</font> in <font color="blue">foreign markets</font>, and as we expand our     <font color="blue">operations</font>, we will become subject to even more foreign <font color="blue">regulations</font></td>
    </tr>
    <tr>
      <td>Our     failure  to  comply,  or <font color="blue">assertions</font> that we fail to comply, with these     <font color="blue">regulations</font>  could have a material adverse effect on our business in a     <font color="blue">particular market</font> or in general</td>
    </tr>
    <tr>
      <td>To the extent we decide to commence or     expand <font color="blue">operations</font> in <font color="blue">additional</font> countries, <font color="blue"><font color="blue">government</font> regulation</font>s in those     countries may prevent or delay entry into, or expansion of <font color="blue">operations</font> in,     those markets</td>
    </tr>
    <tr>
      <td><font color="blue">Government </font><font color="blue">regulations</font> in international markets <font color="blue">could delay</font>     or prevent the <font color="blue">introduction</font>, or require the <font color="blue">reformulation</font> or withdrawal, of     some of our <font color="blue">future products</font></td>
    </tr>
    <tr>
      <td>Our foreign <font color="blue">operations</font> are exposed to <font color="blue">risks associated with exchange rate</font>     <font color="blue">fluctuations</font>,  trade  <font color="blue"><font color="blue">restriction</font>s</font>  and political, economic and social     <font color="blue">instability</font></td>
    </tr>
    <tr>
      <td>We are subject to the risks of doing business abroad, including:       ·       unexpected changes in <font color="blue">regulatory</font> <font color="blue"><font color="blue">requirement</font>s</font>;       ·       export and import <font color="blue"><font color="blue">restriction</font>s</font>, tariffs and other <font color="blue">trade barriers</font>;       ·       <font color="blue">difficult</font>ies in staffing and managing foreign <font color="blue">operations</font>;       ·        longer  payment  cycles  and  problems in <font color="blue">collecting accounts</font>     receivable;       ·       <font color="blue">potential adverse tax consequences</font>;       ·       exchange rate <font color="blue">fluctuations</font>;       ·       <font color="blue">increased risks</font> of piracy and <font color="blue">limits on</font> our ability to enforce our     <font color="blue"><font color="blue">intellectual</font> <font color="blue">property rights</font></font>;       ·       <font color="blue">limits on</font> repatriation of funds; and       ·       <font color="blue">political risks</font> that may limit or <font color="blue">disrupt international sales</font></td>
    </tr>
    <tr>
      <td>28     ______________________________________________________________________       A foreign <font color="blue">government</font> may impose trade or foreign exchange <font color="blue"><font color="blue">restriction</font>s</font> or     increased  tariffs,  which  could <font color="blue">adversely</font> affect our <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>Our     <font color="blue">operations</font> in some <font color="blue">markets also may</font> be <font color="blue">adversely</font> affected by political,     economic and social <font color="blue">instability</font> in <font color="blue">foreign countries</font>, including terrorism</td>
    </tr>
    <tr>
      <td>As we continue to <font color="blue">focus on expanding</font> our existing international <font color="blue">operations</font>,     these and other risks associated with international <font color="blue">operations</font> may increase</td>
    </tr>
    <tr>
      <td>Any <font color="blue">limitations</font> or <font color="blue">interruption</font>s in our foreign <font color="blue">operations</font> could have a     material  adverse  effect  on our business</td>
    </tr>
    <tr>
      <td>In addition, for financial     reporting purposes, results of <font color="blue">operations</font> of our <font color="blue">foreign <font color="blue">subsidiaries</font></font> are     <font color="blue">translated from local currency into</font> US <font color="blue">dollars based on average monthly</font>     <font color="blue">exchange rates</font></td>
    </tr>
    <tr>
      <td>We currently do not hedge our <font color="blue">foreign currency transactions</font>     and are therefore subject to the risk of changes in <font color="blue">exchange rates</font></td>
    </tr>
    <tr>
      <td>Any <font color="blue">future products</font> that we develop may not be <font color="blue">commercially successful</font></td>
    </tr>
    <tr>
      <td>Even if we obtain <font color="blue">regulatory</font> approval for our product <font color="blue">candidates</font> in the     <font color="blue"><font color="blue">United States</font> </font>and other countries, those <font color="blue">products may</font> not be <font color="blue">accepted by</font> the     market</td>
    </tr>
    <tr>
      <td>A  number  of <font color="blue">factors may affect</font> the rate and level of market     <font color="blue">acceptance</font> of our products, including:       ·       labeling <font color="blue"><font color="blue">requirement</font>s</font> or <font color="blue">limitations</font>;       ·       <font color="blue">market <font color="blue">acceptance</font></font> by <font color="blue">practitioners</font> and their patients;       ·        our  ability  to  <font color="blue">successfully</font>  improve  and/or  automate our     <font color="blue"><font color="blue">manufacturing</font> process</font> to allow us to more cost-<font color="blue"><font color="blue">effective</font>ly</font> produce our     <font color="blue">future products</font>, thereby reducing the <font color="blue">price at which</font> we can offer our future     products;       ·       the <font color="blue">effective</font>ness of our <font color="blue">sales efforts</font> and <font color="blue">marketing activities</font>; and       ·       the success of <font color="blue"><font color="blue">competitive</font> products</font></td>
    </tr>
    <tr>
      <td>If  our  current  or  future product <font color="blue">candidates</font> fail to achieve market     <font color="blue">acceptance</font>, our <font color="blue">profitability</font> and <font color="blue">financial condition</font> will suffer</td>
    </tr>
    <tr>
      <td>Our <font color="blue">competitors</font> in the <font color="blue">pharmaceutical</font>, medical device and bio<font color="blue">technology</font>     <font color="blue">industries may</font> have superior products, <font color="blue">manufacturing</font> <font color="blue">capabilities</font>, financial     resources or <font color="blue">marketing position</font></td>
    </tr>
    <tr>
      <td>The  human  healthcare  products  and  services  industry is extremely     <font color="blue">competitive</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">competitors</font> include major <font color="blue">pharmaceutical</font>, medical device     and bio<font color="blue">technology</font> companies</td>
    </tr>
    <tr>
      <td>Most of these <font color="blue">competitors</font> have more extensive     research and <font color="blue">development</font>, marketing and production <font color="blue">capabilities</font> and greater     financial  resources than we do</td>
    </tr>
    <tr>
      <td>Our <font color="blue">future success will depend on</font> our     ability to develop and market <font color="blue"><font color="blue">effective</font>ly</font> our <font color="blue">future products</font> against those     of our <font color="blue">competitors</font></td>
    </tr>
    <tr>
      <td>If our <font color="blue">future products</font> receive <font color="blue">marketing approval</font> but     cannot <font color="blue">compete <font color="blue"><font color="blue">effective</font>ly</font></font> in the marketplace, our results of <font color="blue">operations</font> and     <font color="blue"><font color="blue">financial position will</font> suffer</font></td>
    </tr>
    <tr>
      <td><font color="blue">Difficulties </font>managing growth could <font color="blue">adversely</font> affect our business, operating     results and <font color="blue">financial condition</font></td>
    </tr>
    <tr>
      <td>If we achieve growth in our <font color="blue">operations</font> in the next few years, such growth     could place a strain on our <font color="blue">management</font>, and our administrative, operational     and <font color="blue">financial infrastructure</font></td>
    </tr>
    <tr>
      <td>We would need to hire <font color="blue">additional</font> <font color="blue">management</font>,     financial,  sales and <font color="blue">marketing personnel</font> to manage our <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>In     addition, our ability to manage our future <font color="blue">operations</font> and <font color="blue">growth would</font>     require the <font color="blue">continued improvement</font> of operational, financial and <font color="blue">management</font>     controls, reporting systems and procedures</td>
    </tr>
    <tr>
      <td>If we are unable to manage our     growth  <font color="blue"><font color="blue">effective</font>ly</font>  or  if we are unable to attract <font color="blue">additional</font> highly     <font color="blue">qualified personnel</font>, our business, operating results and <font color="blue">financial condition</font>     may be <font color="blue">materially</font> <font color="blue">adversely</font> affected</td>
    </tr>
    <tr>
      <td>29     ______________________________________________________________________       We are <font color="blue"><font color="blue">dependent</font> on</font> our <font color="blue">key scientific</font> and other <font color="blue">management</font> personnel, and     the loss of any of these <font color="blue">individuals</font> could harm our business</td>
    </tr>
    <tr>
      <td>We are <font color="blue"><font color="blue">dependent</font> on</font> the efforts of our key <font color="blue">management</font> and <font color="blue">scientific staff</font></td>
    </tr>
    <tr>
      <td>The loss of any of these <font color="blue">individuals</font>, or our <font color="blue">inability</font> to recruit and train     <font color="blue">additional</font> key personnel in a <font color="blue">timely manner</font>, could <font color="blue">materially</font> and <font color="blue">adversely</font>     affect our business and our <font color="blue">future prospects</font></td>
    </tr>
    <tr>
      <td>A loss of one or more of our     <font color="blue">current officers</font> or <font color="blue">key personnel could severely</font> and <font color="blue">negatively</font> impact our     <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>We have <font color="blue">employment <font color="blue">agreements</font> with most</font> of our key <font color="blue">management</font>     personnel, but some of these people are employed “at-will” and any of them     may elect to pursue other <font color="blue">opportunities at</font> any time</td>
    </tr>
    <tr>
      <td>We have no present     intention  of obtaining <font color="blue">key man life insurance on</font> any of our executive     officers or key <font color="blue">management</font> personnel</td>
    </tr>
    <tr>
      <td>We will need to attract, train and retain <font color="blue">additional</font> highly qualified senior     <font color="blue">executives</font> and technical and <font color="blue">managerial personnel</font> in the future</td>
    </tr>
    <tr>
      <td>We are in the process of seeking <font color="blue">additional</font> senior <font color="blue">executives</font>, as well as     technical and <font color="blue">managerial staff members</font></td>
    </tr>
    <tr>
      <td>There is a high demand for highly     trained executive, technical and <font color="blue">managerial personnel</font> in our industry</td>
    </tr>
    <tr>
      <td>We do     not  know  whether we will be able to attract, train and retain highly     <font color="blue">qualified technical</font> and <font color="blue">managerial personnel</font> in the future, which could have     a material adverse effect on our business, <font color="blue">financial condition</font> and results     of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>If we are unable to <font color="blue"><font color="blue">effective</font>ly</font> promote our brand and establish a leading     position in the marketplace, our business may fail</td>
    </tr>
    <tr>
      <td>We believe that the importance of brand     <font color="blue"><font color="blue">recognition</font> will increase over</font> time</td>
    </tr>
    <tr>
      <td>In order to gain brand <font color="blue">recognition</font>, we     may increase our marketing and <font color="blue">advertising</font> budgets to create and maintain     brand loyalty</td>
    </tr>
    <tr>
      <td>We do not know whether these <font color="blue">efforts will lead</font> to greater     brand <font color="blue">recognition</font></td>
    </tr>
    <tr>
      <td>If we are unable to <font color="blue"><font color="blue">effective</font>ly</font> promote our brand and     establish a <font color="blue">leading position</font> in the marketplace, our <font color="blue">operations</font> will suffer</td>
    </tr>
    <tr>
      <td>Our ability to achieve <font color="blue">commercial success will depend</font> in part on obtaining     and  maintaining  <font color="blue">patent protection</font> and <font color="blue">trade secret protection</font> of our     <font color="blue">technology</font> and <font color="blue">future products</font>, as well as <font color="blue">successfully</font> defending these     <font color="blue">patents against <font color="blue">third party</font> challenges</font></td>
    </tr>
    <tr>
      <td>If we are unable to obtain and     maintain  protection  for  our  <font color="blue">intellectual</font>  property and <font color="blue">proprietary</font>     <font color="blue">technology</font>,  the  value  of our <font color="blue">technology</font> and <font color="blue">future products</font> will be     <font color="blue">adversely</font> affected, and we will not be able to protect our <font color="blue">technology</font> from     <font color="blue">unauthorized use by third parties</font></td>
    </tr>
    <tr>
      <td>Our  long-term  success  largely  depends  on  our  ability  to market     <font color="blue">technologically</font>  <font color="blue">competitive</font>  future  products  and  to  protect those     <font color="blue">technological creations</font></td>
    </tr>
    <tr>
      <td>In order to do so we must:       ·       obtain and <font color="blue">protect commercially</font> valuable patents or the rights to     <font color="blue">patents both domestically</font> and abroad;       ·       operate <font color="blue">without infringing upon</font> the <font color="blue">proprietary</font> rights of others;     and       ·       prevent others from <font color="blue">successfully</font> challenging or infringing our     <font color="blue">proprietary</font> rights</td>
    </tr>
    <tr>
      <td>As of <font color="blue">December </font>31, 2005, we had 6 issued US patents, 9 pending US patent     <font color="blue">application</font>s, 27 foreign patents and 50 pending foreign patent <font color="blue">application</font>s</td>
    </tr>
    <tr>
      <td>If we fail to obtain or maintain these <font color="blue">protections</font>, we may not be able to     <font color="blue">prevent third parties from using</font> our <font color="blue">proprietary</font> rights</td>
    </tr>
    <tr>
      <td>We will be able to     protect our <font color="blue">proprietary</font> rights from unauthorized use only to the extent that     these rights are <font color="blue">covered by valid</font> and <font color="blue">enforceable patents</font> or are <font color="blue"><font color="blue">effective</font>ly</font>     maintained <font color="blue">as trade secrets</font></td>
    </tr>
    <tr>
      <td>The patent situation in the markets in which we compete is <font color="blue">highly uncertain</font>     and <font color="blue">involves complex legal</font> and <font color="blue">scientific questions</font></td>
    </tr>
    <tr>
      <td>It may be <font color="blue">difficult</font> to     obtain <font color="blue">additional</font> patents relating to our <font color="blue">technology</font></td>
    </tr>
    <tr>
      <td>30     ______________________________________________________________________       Furthermore, any changes in, or <font color="blue">unexpected interpretations</font> of, the patent     laws may <font color="blue">adversely</font> affect our ability to enforce our <font color="blue">patent position</font></td>
    </tr>
    <tr>
      <td>Other risks and <font color="blue">uncertainties</font> that we <font color="blue">face <font color="blue">with respect</font></font> to our patents and     other <font color="blue">proprietary</font> rights include the following:       ·       the inventors of the <font color="blue">inventions</font> covered by each of our pending     patent <font color="blue">application</font>s might not have been the first to make such <font color="blue">inventions</font>;       ·        because  the  information contained in patent <font color="blue">application</font>s is     <font color="blue">generally</font> not <font color="blue">publicly available</font>, we might not have been the first to file     patent <font color="blue">application</font>s for these <font color="blue">inventions</font> or similar <font color="blue">technology</font>;       ·       the future and pending <font color="blue">application</font>s we will file or have filed, or     to which we will or do have exclusive rights, may not result in issued     patents or may take <font color="blue">longer than</font> we expect to result in <font color="blue">issued patents</font>;       ·       the claims of any patents that are <font color="blue">issued may</font> not provide meaningful     protection;       ·       our <font color="blue">issued patents</font> may not provide a basis for <font color="blue">commercially viable</font>     products or may not be valid or enforceable;       ·       we might not be able to develop <font color="blue">additional</font> <font color="blue">proprietary</font> <font color="blue">technologies</font>     that are patentable;       ·       the <font color="blue">patents licensed</font> or issued to us may not provide a <font color="blue">competitive</font>     advantage;       ·        patents  issued  to other companies, <font color="blue">universities</font> or research     <font color="blue">institutions may harm</font> our ability to do business;       ·        other  companies,  <font color="blue">universities</font>  or <font color="blue">research institutions may</font>     <font color="blue">in<font color="blue">dependent</font>ly</font> develop similar or alternative <font color="blue">technologies</font> or duplicate our     <font color="blue">technologies</font> and <font color="blue">commercialize</font> discoveries that we attempt to patent;       ·       other companies, <font color="blue">universities</font> or <font color="blue">research institutions may</font> design     around <font color="blue">technologies</font> we have licensed, patented or developed; and       ·       many of our patent claims are method, rather than <font color="blue">composition</font> of     matter,  claims</td>
    </tr>
    <tr>
      <td>Generally, <font color="blue">composition</font> of matter claims are easier to     enforce and are more <font color="blue">difficult</font> to <font color="blue">circumvent</font></td>
    </tr>
    <tr>
      <td>We have obtained some of our <font color="blue">rights from third parties</font></td>
    </tr>
    <tr>
      <td>If our <font color="blue">agreements</font>     with  these parties do not appear as we anticipate our business may be     <font color="blue">adversely</font> affected</td>
    </tr>
    <tr>
      <td>The rights to some of our patent <font color="blue">application</font>s were obtained in a purchase     <font color="blue">agreement with</font> a <font color="blue">third party</font></td>
    </tr>
    <tr>
      <td>If this <font color="blue">purchase agreement</font> is <font color="blue">found invalid</font> or     there are <font color="blue">otherwise disputes</font> regarding the invention and <font color="blue">corresponding</font>     <font color="blue">ownership rights</font> in the invention, we may not be able to <font color="blue">market future</font>     products  covered  by the license</td>
    </tr>
    <tr>
      <td>We <font color="blue">may enter into collaboration</font> and     cooperation <font color="blue">agreements</font> with third parties from time to time to develop new     <font color="blue">technologies</font></td>
    </tr>
    <tr>
      <td>We may not be able to use and claim <font color="blue">proprietary</font> rights to the     <font color="blue">technology</font> resulting <font color="blue">from collaboration</font> and cooperation <font color="blue">agreements</font>, which     may <font color="blue">adversely</font> affect our business</td>
    </tr>
    <tr>
      <td>Our business may be harmed, and we may incur substantial costs as a result     of <font color="blue">litigation</font> or other <font color="blue">proceedings</font> relating to patent and other <font color="blue">intellectual</font>     <font color="blue">property rights</font></td>
    </tr>
    <tr>
      <td>A <font color="blue">third party</font> may assert that we, one of our <font color="blue">subsidiaries</font> or one of our     strategic  <font color="blue">collaborators</font>  has  infringed  his,  her or its patents and     <font color="blue">proprietary</font> rights or challenge the validity of our patents and <font color="blue">proprietary</font>     rights</td>
    </tr>
    <tr>
      <td>Likewise, we may need to resort to <font color="blue">litigation</font> to enforce our patent     rights or to determine the scope and validity of a <font color="blue">third party</font>’s <font color="blue">proprietary</font>     rights</td>
    </tr>
    <tr>
      <td>31     ______________________________________________________________________       The outcome of these <font color="blue">proceedings</font> is uncertain and could <font color="blue">significant</font>ly harm     our business</td>
    </tr>
    <tr>
      <td>If we do not prevail in this type of <font color="blue">litigation</font>, we or our     strategic <font color="blue">collaborators</font> may be required to:       ·       <font color="blue">pay monetary damages</font>;       ·       expend time and funding to redesign our Isolagen Process so that it     does not infringe others’ patents while still allowing us to compete in the     <font color="blue">market with</font> a <font color="blue">substantially</font> similar product;       ·       obtain a license in order to continue <font color="blue">manufacturing</font> or marketing the     <font color="blue">affected products</font> or services, and <font color="blue">pay license fees</font> and royalties</td>
    </tr>
    <tr>
      <td><font color="blue">This     </font>license may be non-exclusive, giving our <font color="blue">competitors</font> access to the same     <font color="blue">intellectual</font> property, or the <font color="blue">patent owner may</font> require that we grant a     cross-license to our patented <font color="blue">technology</font>; or       ·       stop research and <font color="blue">commercial activities</font> relating to the affected     products or services if a license is not <font color="blue">available on</font> acceptable terms, if     at all</td>
    </tr>
    <tr>
      <td>Any of these events could <font color="blue">adversely</font> affect our business strategy and the     value of our business</td>
    </tr>
    <tr>
      <td>In addition, the defense and <font color="blue">prosecution</font> of <font color="blue">intellectual</font> property suits,     interferences, oppositions and related legal and administrative <font color="blue">proceedings</font>     in the <font color="blue"><font color="blue">United States</font> </font>and elsewhere, even if resolved in our favor, could be     expensive and time consuming and could divert financial and managerial     resources</td>
    </tr>
    <tr>
      <td>Some of our <font color="blue">competitors</font> may be able to sustain the costs of     complex patent <font color="blue">litigation</font> more <font color="blue"><font color="blue">effective</font>ly</font> than we can because they have     <font color="blue">substantially</font> greater financial resources</td>
    </tr>
    <tr>
      <td>We  may  not  be successful in our efforts to develop commercial-scale     <font color="blue">manufacturing</font> <font color="blue">technology</font> and methods</td>
    </tr>
    <tr>
      <td><font color="blue">Primarily  </font>through  internal  research,  we  are  seeking to develop a     <font color="blue">commercially viable</font> design and <font color="blue">production process</font> for our <font color="blue">future products</font>,     <font color="blue">as well as new areas</font> of <font color="blue">application</font> for our Isolagen Process</td>
    </tr>
    <tr>
      <td>If we are     unable  to  develop <font color="blue">suitable techniques</font> to produce and <font color="blue">manufacture</font> our     <font color="blue">technology</font> for the <font color="blue">commercial market</font> or <font color="blue">additional</font> areas of <font color="blue">application</font> for     our Isolagen Process, our business <font color="blue">prospects will suffer</font></td>
    </tr>
    <tr>
      <td>We may be liable for product <font color="blue">liability</font> claims not <font color="blue">covered by insurance</font></td>
    </tr>
    <tr>
      <td><font color="blue">Physicians </font>that use our <font color="blue">dermal product</font>, or any of our <font color="blue">future products</font>, and     patients who have <font color="blue">been treated by</font> our <font color="blue">dermal product</font>, or any of our future     products, may bring product <font color="blue">liability</font> claims <font color="blue">against us</font></td>
    </tr>
    <tr>
      <td>While we have     taken, and continue to take, what we believe are <font color="blue">appropriate precautions</font>, we     may be unable to avoid <font color="blue">significant</font> <font color="blue">liability</font> exposure</td>
    </tr>
    <tr>
      <td>We <font color="blue">currently intend</font>     to obtain and keep in force product <font color="blue">liability</font> insurance</td>
    </tr>
    <tr>
      <td>Any insurance we obtain may not <font color="blue">provide adequate coverage</font>     against any asserted claims</td>
    </tr>
    <tr>
      <td>In addition, regardless of merit or eventual     outcome, product <font color="blue">liability</font> claims may result in:       ·       diversion of <font color="blue">management</font>’s time and attention;       ·       <font color="blue">expenditure</font> of large amounts of cash on legal fees, expenses and     payment of damages;       ·       <font color="blue">decreased demand</font> for our products or any of our <font color="blue">future products</font> and     services; or       ·       injury to our reputation</td>
    </tr>
    <tr>
      <td>If we are unable to keep <font color="blue">up with <font color="blue">rapid technological</font></font> changes, our future     <font color="blue">products may</font> become obsolete or unmarketable</td>
    </tr>
    <tr>
      <td>Our industry is characterized by <font color="blue">significant</font> and <font color="blue">rapid technological</font> change</td>
    </tr>
    <tr>
      <td>Although we attempt to expand our technological <font color="blue">capabilities</font> in order to     remain <font color="blue">competitive</font>, research and <font color="blue">discoveries by others</font>       32     ______________________________________________________________________       may make our <font color="blue">future products</font> obsolete</td>
    </tr>
    <tr>
      <td>If we cannot <font color="blue">compete <font color="blue"><font color="blue">effective</font>ly</font></font> in     the marketplace, our potential for <font color="blue">profitability</font> and <font color="blue">financial position will</font>     suffer</td>
    </tr>
    <tr>
      <td>Our <font color="blue"><font color="blue">acquisition</font>s</font> of companies or <font color="blue">technologies</font> may result in <font color="blue">disruption</font>s in     business and diversion of <font color="blue">management</font> attention</td>
    </tr>
    <tr>
      <td>We  may  make  <font color="blue"><font color="blue">acquisition</font>s</font>  of  <font color="blue">complementary</font>  companies, products or     <font color="blue">technologies</font></td>
    </tr>
    <tr>
      <td>Any  <font color="blue"><font color="blue">acquisition</font>s</font>  will require the <font color="blue">assimilation</font> of the     <font color="blue">operations</font>,  products and personnel of the acquired <font color="blue">businesses</font> and the     training and motivation of these <font color="blue">individuals</font></td>
    </tr>
    <tr>
      <td><font color="blue">Acquisitions </font><font color="blue">may disrupt</font> our     <font color="blue">operations</font> and divert <font color="blue">management</font>’s attention from day-to-day <font color="blue">operations</font>,     <font color="blue">which could impair</font> our relationships with current employees, customers and     <font color="blue">strategic partners</font></td>
    </tr>
    <tr>
      <td>We may also have to, or we may choose to, incur debt or     issue <font color="blue">equity securities</font> to pay for any future <font color="blue"><font color="blue">acquisition</font>s</font></td>
    </tr>
    <tr>
      <td>The issuance of     <font color="blue">equity securities</font> for an <font color="blue"><font color="blue">acquisition</font> could</font> be <font color="blue">substantially</font> dilutive to our     <font color="blue">stockholders</font></td>
    </tr>
    <tr>
      <td>In addition, our results of <font color="blue">operations</font> may suffer because of     <font color="blue">acquisition</font>-related costs or <font color="blue">amortization</font> or <font color="blue">impairment costs</font> for acquired     goodwill and other <font color="blue">intangible assets</font></td>
    </tr>
    <tr>
      <td>If <font color="blue">management</font> is unable to fully     integrate acquired <font color="blue">businesses</font>, products, <font color="blue">technologies</font> or <font color="blue">personnel with</font>     existing  <font color="blue">operations</font>,  we may not receive the <font color="blue">intended benefits</font> of the     <font color="blue"><font color="blue">acquisition</font>s</font></td>
    </tr>
    <tr>
      <td>As  of the date of this report, we are not party to any     <font color="blue">agreements</font>, written or oral, for the <font color="blue">acquisition</font> of any company, product or     <font color="blue">technology</font></td>
    </tr>
    <tr>
      <td>Our business, <font color="blue">which depends on</font> a small number of <font color="blue">facilities</font>, is vulnerable     to natural disasters, <font color="blue">telecommunication</font> and information <font color="blue">systems failures</font>,     terrorism and similar problems, and we are not <font color="blue">fully insured</font> for losses     caused by all of these <font color="blue">incidents</font></td>
    </tr>
    <tr>
      <td>We currently conduct <font color="blue">operations</font> in three main <font color="blue">facilities</font> located in Exton,     Pennsylvania, Houston, Texas and London, England</td>
    </tr>
    <tr>
      <td>We <font color="blue">also purchased land</font> and     <font color="blue">two buildings located</font> in <font color="blue">Switzerland in April </font>2005</td>
    </tr>
    <tr>
      <td>The majority of this     <font color="blue">acquisition</font> is <font color="blue">currently under construction</font> and is not considered fully     operational</td>
    </tr>
    <tr>
      <td>Our <font color="blue">facilities</font> could be damaged by fire, floods, power loss,     <font color="blue">telecommunication</font> and information <font color="blue">systems failures</font> or similar events</td>
    </tr>
    <tr>
      <td>Our     insurance policies have limited <font color="blue">coverage levels</font> for loss or damages in these     events and may not <font color="blue">adequately compensate us</font> for any losses that may occur</td>
    </tr>
    <tr>
      <td>In addition, terrorist acts or acts of war may cause harm to our employees     or damage our <font color="blue">facilities</font></td>
    </tr>
    <tr>
      <td>The potential for <font color="blue">future <font color="blue">terrorist attacks</font></font>, the     national and international responses to <font color="blue">terrorist attacks</font> or perceived     threats  to <font color="blue">national security</font>, and other acts of war or hostility have     created many economic and political <font color="blue">uncertainties</font> that could <font color="blue">adversely</font>     affect  our  business and results of <font color="blue">operations</font> in ways that we cannot     predict, and could cause our stock price to fluctuate or decline</td>
    </tr>
    <tr>
      <td>Our stock price has <font color="blue">been volatile</font> and could experience substantial declines</td>
    </tr>
    <tr>
      <td>The <font color="blue">market price</font> of our <font color="blue">common stock</font> has experienced, and <font color="blue">may continue</font> to     experience, <font color="blue">significant</font> <font color="blue">volatility</font></td>
    </tr>
    <tr>
      <td>The value of our <font color="blue">common stock</font> may decline regardless of our operating     performance or prospects</td>
    </tr>
    <tr>
      <td>Factors <font color="blue">affecting</font> our <font color="blue">market price</font> include, but     are not limited to:       ·        the  success  or  failure of our product <font color="blue">development</font> efforts,     <font color="blue">especially</font> those related to obtaining <font color="blue">regulatory</font> approvals domestically and     <font color="blue">internationally</font>;       ·        the <font color="blue">implementation</font> of improved and/or automated <font color="blue">manufacturing</font>     processes;       ·       <font color="blue">technological innovations</font> developed by us or our <font color="blue">competitors</font>;       ·       <font color="blue">variations</font> in our operating results and the extent to which we     achieve our key business targets;       ·       <font color="blue">differences between</font> our reported results and those expected by     investors and <font color="blue">securities analysts</font>;       33     ______________________________________________________________________       ·       <font color="blue">market reaction</font> to any <font color="blue"><font color="blue">acquisition</font>s</font> or <font color="blue">joint ventures</font> announced by     us or our <font color="blue">competitors</font>; and       ·        <font color="blue">development</font>s  <font color="blue">with respect</font> to the class and <font color="blue">derivative</font> action     <font color="blue">litigation</font> of which we are currently <font color="blue">defendants</font></td>
    </tr>
    <tr>
      <td>In addition, in <font color="blue">recent years</font>, the <font color="blue">stock market</font> in general, and the market     for <font color="blue">life sciences companies</font> in particular, have experienced <font color="blue">significant</font>     price and volume <font color="blue">fluctuations</font></td>
    </tr>
    <tr>
      <td>This <font color="blue">volatility</font> has affected the market     prices of <font color="blue">securities issued by</font> many companies, often for <font color="blue">reasons unrelated</font>     to their operating performance, and it may <font color="blue">adversely</font> affect the price of our     <font color="blue">common stock</font></td>
    </tr>
    <tr>
      <td>In the past, securities class action <font color="blue">litigation</font> has often been     instituted  following  periods  of <font color="blue">volatility</font> in the <font color="blue">market price</font> of a     company’s securities</td>
    </tr>
    <tr>
      <td>The current class and <font color="blue">derivative</font> action suits or a     <font color="blue">future securities</font> class action suit <font color="blue">against us</font> could result in potential     <font color="blue">liabilities</font>, substantial costs and the diversion of <font color="blue">management</font>’s attention     and resources, regardless of whether we win or lose</td>
    </tr>
    <tr>
      <td>We have not declared any dividends on our <font color="blue">common stock</font> to date, and we have     <font color="blue">no intention</font> of declaring dividends in the <font color="blue">foreseeable future</font></td>
    </tr>
    <tr>
      <td>The decision to <font color="blue">pay cash dividends on</font> our <font color="blue">common stock</font> rests with our Board     of Directors and will depend on our earnings, unencumbered cash, capital     <font color="blue"><font color="blue">requirement</font>s</font> and <font color="blue">financial condition</font></td>
    </tr>
    <tr>
      <td>We do not anticipate declaring any     dividends in the <font color="blue">foreseeable future</font>, as we intend to use any <font color="blue">excess cash</font> to     fund our <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td><font color="blue">Investors </font>in our <font color="blue">common stock</font> should not expect to     receive dividend income on their <font color="blue">investment</font>, and investors will be <font color="blue">dependent</font>     on  the  <font color="blue">appreciation</font>  of  our  <font color="blue">common stock</font> to earn a return on their     <font color="blue">investment</font></td>
    </tr>
    <tr>
      <td><font color="blue">Provisions </font>in our charter <font color="blue">documents</font> could prevent or delay <font color="blue">stockholders</font>’     attempts to replace or remove current <font color="blue">management</font></td>
    </tr>
    <tr>
      <td>Our charter <font color="blue">documents</font> provide for <font color="blue">staggered terms</font> for the members of our     <font color="blue">Board of Directors</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">Board of Directors</font> is <font color="blue">divided into three staggered</font>     classes, and <font color="blue">each director serves</font> a term of <font color="blue">three years</font></td>
    </tr>
    <tr>
      <td>At <font color="blue">stockholders</font>’     <font color="blue">meetings only</font> those <font color="blue">directors</font> comprising one of the <font color="blue">three classes will</font> have     completed their term and be subject to re-election or <font color="blue">replacement</font></td>
    </tr>
    <tr>
      <td>In addition, our <font color="blue">Board of Directors</font> is authorized to issue “blank check:”     preferred stock, with designations, rights and <font color="blue">preferences as</font> they may     determine</td>
    </tr>
    <tr>
      <td>Accordingly, our <font color="blue">Board of Directors</font> may, without stockholder     approval,  <font color="blue">issue shares</font> of preferred stock with dividend, liquidation,     conversion, voting or other rights that could <font color="blue">adversely</font> affect the voting     power or other rights of the holders of our <font color="blue">common stock</font></td>
    </tr>
    <tr>
      <td>This type of     <font color="blue">preferred stock could also</font> be issued to discourage, delay or prevent a     change in our control</td>
    </tr>
    <tr>
      <td>The use of a staggered <font color="blue">Board of Directors</font> and the ability to issue “blank     check”  preferred  stock are traditional anti-takeover measures</td>
    </tr>
    <tr>
      <td><font color="blue">These     </font>provisions  in  our charter <font color="blue">documents</font> make it <font color="blue">difficult</font> for a majority     stockholder to <font color="blue">gain control</font> of the <font color="blue">Board of Directors</font> and of our company</td>
    </tr>
    <tr>
      <td>These  <font color="blue">provisions may</font> be <font color="blue">beneficial</font> to our <font color="blue">management</font> and our Board of     <font color="blue">Directors  </font>in a <font color="blue">hostile <font color="blue">tender offer</font></font> and may have an adverse <font color="blue">impact on</font>     <font color="blue">stockholders</font> who may want to <font color="blue">participate</font> in such a <font color="blue">tender offer</font>, or who may     want to replace some or all of the members of our <font color="blue">Board of Directors</font></td>
    </tr>
    <tr>
      <td><font color="blue">Provisions </font> in  our <font color="blue">bylaws provide</font> for <font color="blue">indemnification</font> of officers and     <font color="blue">directors</font>, which could require us to direct funds away from our business and     <font color="blue">future products</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">bylaws provide</font> for the <font color="blue">indemnification</font> of our officers and <font color="blue">directors</font></td>
    </tr>
    <tr>
      <td>We     may be required to <font color="blue">advance costs incurred by</font> an officer or director and to     pay  judgments, fines and <font color="blue">expenses incurred by</font> an officer or director,     including reasonable attorneys’ fees, as a result of actions or <font color="blue">proceedings</font>     in which our officers and <font color="blue">directors</font> are <font color="blue">involved by reason</font> of being or     having been an officer or director of our company</td>
    </tr>
    <tr>
      <td>34     ______________________________________________________________________       Funds paid in <font color="blue">satisfaction</font> of judgments, fines and <font color="blue">expenses may</font> be funds we     need for the operation of our business and the <font color="blue">development</font> of our product     <font color="blue">candidates</font>, thereby <font color="blue">affecting</font> our ability to <font color="blue">attain <font color="blue">profitability</font></font></td>
    </tr>
    <tr>
      <td>Future sales of our <font color="blue">common stock</font> may depress our stock price</td>
    </tr>
    <tr>
      <td>The <font color="blue">market price</font> of our <font color="blue">common stock</font> could decline as a result of sales of     substantial amounts of our <font color="blue">common stock</font> in the <font color="blue">public market</font>, or as a result     of the <font color="blue">perception</font> that these <font color="blue">sales could</font> occur</td>
    </tr>
    <tr>
      <td>In addition, these factors     could make it more <font color="blue">difficult</font> for us to <font color="blue">raise funds through future offerings</font>     of <font color="blue">common stock</font></td>
    </tr>
    <tr>
      <td>As of <font color="blue">December </font>31, 2005, there are 34cmam260cmam383 shares of     <font color="blue">common stock</font> issued and 30cmam260cmam383 outstanding</td>
    </tr>
    <tr>
      <td>All of our outstanding     shares are freely transferable without <font color="blue">restriction</font> or further <font color="blue">registration</font>     under <font color="blue">the Securities Act</font></td>
    </tr>
    <tr>
      <td>There is a limited <font color="blue">public trading market</font> for our <font color="blue">common stock</font></td>
    </tr>
    <tr>
      <td>Without an     active trading market, there can be no assurance of any liquidity or resale     value of our <font color="blue">common stock</font>, and <font color="blue">stockholders</font> may be required to hold shares     of our <font color="blue">common stock</font> for an <font color="blue">indefinite period</font> of time</td>
    </tr>
    <tr>
      <td>As  a  public  company,  our business is subject to numerous reporting     <font color="blue"><font color="blue">requirement</font>s</font>  that  are  currently and <font color="blue">continuously</font> evolving and could     <font color="blue">substantially</font>  increase our operating expenses and divert <font color="blue">management</font>’s     attention from the operation of our business</td>
    </tr>
    <tr>
      <td>The Sarbanes-Oxley Act of 2002, which became law in July 2002, has required     changes in some of our corporate governance, securities disclosure and     <font color="blue">compliance practices</font></td>
    </tr>
    <tr>
      <td>In response to the <font color="blue"><font color="blue">requirement</font>s</font> of that Act, the SEC     and the American Stock Exchange have <font color="blue">promulgated new rules</font> and listing     standards  covering  a  variety of subjects</td>
    </tr>
    <tr>
      <td><font color="blue">Compliance </font>with these new     rules and  <font color="blue">listing standards</font> has <font color="blue">significant</font>ly increased our legal and     financial and <font color="blue">accounting costs</font>, and we expect these <font color="blue">increased costs</font> to     continue</td>
    </tr>
    <tr>
      <td>In addition, the <font color="blue"><font color="blue">requirement</font>s</font> have taxed a <font color="blue">significant</font> amount of     <font color="blue">management</font>’s and the <font color="blue">Board of Directors</font>’ time and resources</td>
    </tr>
    <tr>
      <td>Likewise, these     <font color="blue">development</font>s  may  make it more <font color="blue">difficult</font> for us to attract and retain     qualified  members of our board of <font color="blue">directors</font>, particularly in<font color="blue">dependent</font>     <font color="blue">directors</font>, or <font color="blue">qualified executive officers</font></td>
    </tr>
    <tr>
      <td>As  <font color="blue">directed by</font> Section 404 of the Sarbanes-Oxley Act, the SEC adopted     rules requiring <font color="blue">public companies</font> to include a report of <font color="blue">management</font> on the     company’s internal controls over financial reporting in their annual reports     on Form 10-K that contains an assessment by <font color="blue">management</font> of the <font color="blue">effective</font>ness     of the company’s internal controls over financial reporting</td>
    </tr>
    <tr>
      <td>In addition,     the <font color="blue">public accounting firm auditing</font> the company’s financial statements must     attest to and report on <font color="blue">management</font>’s assessment of the <font color="blue">effective</font>ness of the     company’s internal controls over financial reporting</td>
    </tr>
    <tr>
      <td>This <font color="blue">requirement</font> is     applicable to our <font color="blue">current annual</font> report on Form 10-K and for all future     annual reports</td>
    </tr>
    <tr>
      <td>Lack of <font color="blue">effective</font>ness of internal controls over financial reporting could     <font color="blue">adversely</font> affect the value of our securities</td>
    </tr>
    <tr>
      <td>In<font color="blue">effective</font> internal controls over our financial reporting have occurred in     the past and may arise in the future</td>
    </tr>
    <tr>
      <td>As a consequence, our investors could     lose confidence in the re<font color="blue">liability</font> of our financial statements, which could     result in a decrease in the value of our securities</td>
    </tr>
  </tbody>
</table>